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ABSTRACT

MODELING SPORADIC TUMOR FORMATION DRIVEN BY TELOMERE
DYSFUNCTION IN THE GASTROINTESTINAL TRACT
Publication No.__________

Suzanne S. Chan
Supervisory Professor: Sandy Chang, M.D., Ph.D.

Colorectal cancer is a complex disease that is thought to arise when cells accumulate
mutations that allow for uncontrolled growth. There are several recognized mechanisms for
generating such mutations in sporadic colon cancer; one of which is chromosomal instability
(CIN). One hypothesized driver of CIN in cancer is the improper repair of dysfunctional
telomeres. Telomeres comprise the linear ends of chromosomes and play a dual role in
cancer. Its length is maintained by the ribonucleoprotein, telomerase, which is not a normally
expressed in somatic cells and as cells divide, telomeres continuously shorten. Critically
shortened telomeres are considered dysfunctional as they are recognized as sites of DNA
damage and cells respond by entering into replicative senescence or apoptosis, a process that
is p53-dependent and the mechanism for telomere-induced tumor suppression. Loss of this
checkpoint and improper repair of dysfunctional telomeres can initiate a cycle of fusion,
bridge and breakage that can lead to chromosomal changes and genomic instability, a process
that can lead to transformation of normal cells to cancer cells. Mouse models of telomere
dysfunction are currently based on knocking out the telomerase protein or RNA component;
however, the naturally long telomeres of mice require multiple generational crosses of
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telomerase null mice to achieve critically short telomeres. Shelterin is a complex of six core
proteins that bind to telomeres specifically. Pot1a is a highly conserved member of this
complex that specifically binds to the telomeric single-stranded 3’ G-rich overhang. Previous
work in our lab has shown that Pot1a is essential for chromosomal end protection as deletion
of Pot1a in murine embryonic fibroblasts (MEFs) leads to open telomere ends that initiate a
DNA damage response mediated by ATR, resulting in p53-dependent cellular senescence.
Loss of Pot1a in the background of p53 deficiency results in increased aberrant homologous
recombination at telomeres and elevated genomic instability, which allows Pot1a-/-, p53-/MEFs to form tumors when injected into SCID mice. These phenotypes are similar to those
seen in cells with critically shortened telomeres.
In this work, we created a mouse model of telomere dysfunction in the
gastrointestinal tract through the conditional deletion of Pot1a that recapitulates the
microscopic features seen in severe telomere attrition. Combined intestinal loss of Pot1a and
p53 lead to formation of invasive adenocarcinomas in the small and large intestines. The
tumors formed with long latency, low multiplicity and had complex genomes due to
chromosomal instability, features similar to those seen in sporadic human colorectal cancers.
Taken together, we have developed a novel mouse model of intestinal tumorigenesis based
on genomic instability driven by telomere dysfunction.
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INTRODUCTION
Colon cancer and chromosomal instability
Colon cancer is the third most common cause of cancer, as well as the third leading
cause of cancer death in both men and women in the United States(ACS, 2010). Cancer is a
complex disease that arises when cells accumulate mutations that allow for uncontrolled
growth. The progression of colorectal tumorigenesis has been characterized as a step-wise
progression from adenoma to carcinoma to metastasic disease(Fearon and Vogelstein, 1990)
as these mutations accumulate (Figure 1). Some of the important genes involved in some of
the transitions are well known, such as activation of the Wnt signaling pathway especially
through loss of APC(Goss and Groden, 2000). However, recent work with cancer genomics
have revealed that colorectal cancer cells harbor very complex genomes with a multitude of
genetic changes, so there are may be many other genes important for cancer progression,
especially the metastatic transition, that have yet to be elucidated.
There are several mechanisms that drive the accumulation of genetic alterations,
which can fuel colon cancer formation and progression. Genetic alterations can include
subtle sequence changes, alterations in chromosome numbers, chromosome translocations
and gene amplifications(Lengauer et al., 1997). These types of changes can be a consequence
of chromosomal instability or defects in the DNA repair pathways(Markowitz and
Bertagnolli, 2009). The mismatch repair (MMR) pathway is one such DNA repair
mechanism that is found in colon cancers. Inactivation of MMR genes, such as MLH1 or
MSH2, leads to a phenotype called microsatellite instability (MSI), which targets simple
repeat sequences in the genome(Rajagopalan et al., 2003). MSI is most associated with
patients with hereditary
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Figure 1: The Vogelstein model of colon cancer progression. Colorectal cancers
develop first as small benign adenomas and follow a progression to malignant
adenocarcinomas and finally to metastasis. Some of the genetic alterations associated
with various steps of the pathway have been elucidated and are outlined above (dotted
boxes).
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non-polyposis colorectal cancer (HNPCC), but can also be seen in 15% of sporadic
tumors(Markowitz and Bertagnolli, 2009; Rajagopalan et al., 2003).
On the other hand, chromosomal instability (CIN) is seen in 85% of sporadic colon
cancers and is thought to be a major driver of genomic instability(Rajagopalan et al., 2003).
CIN can cause cells to gain or lose large pieces or entire chromosomes leading to aneuploidy
and gene copy number variations (CNV)(Lengauer et al., 1997; Rajagopalan et al., 2003).
Here, we will explore one mechanism that may be involved in driving CIN during
tumorigenesis: dysfunctional telomeres.

The telomere-cancer paradox
Telomeres are located at the terminal ends of chromosomes. They consist of tandem
TTAGGG repeats and end with a 3’ single stranded G-rich overhang (Figure 2). This
overhang is thought to invade the upstream duplex telomere DNA to effectively hide the end
and create a structure called a t-loop(Griffith et al., 1999). It is bound by a complex of
telomere specific proteins called shelterin(de Lange, 2005). The main function of telomeres
is to protect the chromosomal ends from being recognized as sites of DNA damage or being
exposed to nuclease degradation with subsequent loss of genetic information(Verdun and
Karlseder, 2007). The length of telomeres can be maintained by a ribonucleoprotein called
telomerase, which consists of two main components: a reverse transcriptase protein (TERT)
and a RNA component (TERC) that serves as a template for elongation.
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TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG
-3’
AATCCC AATCCCAATCCCAATCCCAATCCCAATCCCAATCCC -5’
3’ G-rich overhang
(50-500nt)

t-loop

Figure 2: The structure of telomeres. Telomeres are located at the terminal ends of
chromosomes. They consist of tandem TTAGGG repeats and end with a 3’ single
stranded G-rich overhang. This overhang is thought to invade the upstream duplex
telomere DNA that effectively hides the end and creating a structure called a t-loop.
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In humans, telomerase activity is in limited to germ cells and stem cells, but absent in
most somatic cells. Without telomerase maintenance, the overall length of telomeres shortens
with each cell division due the inability of DNA replication machinery to fully replicate the
lagging strand DNA, a characteristic termed the end replication problem. It is estimated that
humans lose between 2-4 kb of telomeric DNA in a lifetime. Considering human telomere
lengths average 8-12kb, this amount of loss may be significant and might play a role in
organismal aging(Blasco, 2007). Increasing age is the biggest risk factor for sporadic colon
cancer formation, so it stands to reason that telomeres may provide the link between aging
and cancer(DePinho, 2000). Accordingly, telomere length has been shown to correlate with
age in normal intestinal mucosa(Rampazzo et al.). Furthermore, telomeres in colorectal
tumor tissue are shorter than the surrounding normal mucosa(Rampazzo et al.). Therefore it
is postulated that telomere erosion may be a key initiating event in the colon tumor
formation.
Telomeres plays a dual role in cancer (Artandi and DePinho; Deng et al., 2008). First,
there is a limit to the amount of telomere attrition that a cell can tolerate. This phenomenon
was originally described by Hayflick and Moorhead, who observed that primary human
diploid fibroblasts cannot be cultured indefinitely(Hayflick and Moorhead, 1961). There is a
limit to the number of population doublings that a culture can be passaged, after which the
cells enter into a state of permanent cell cycle arrest termed replicative senescence. This
checkpoint is the basis of the first half of the telomere-cancer paradox: telomere-dependent
tumor suppression(Deng et al., 2008).
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Replicative senescence is thought to be a consequence of the DNA damage response
to telomere attrition. Senescent fibroblasts stained positively for markers of DNA damage,
such as phosphorylated histone H2AX (γ-H2AX) and p53 binding protein 1 (53BP1)(d'Adda
di Fagagna et al., 2003). Critically short telomeres also activate sensors of DNA damage such
as the phosphatidylinositol 3-kinase (PIKKs): ataxia telangiectasia mutated (ATM) and
ataxia telangiectasia- and Rad3- related protein (ATR)(d'Adda di Fagagna et al., 2003).
These proteins in turn activate the downstream transducers, CHK1 and CHK2, which go on
to activate p53(Gire et al., 2004),

the protein that ultimately triggers cell cycle

arrest/senescence through p21. While the Ink4a/Rb pathway may also play a role in this
process that is less understood (Jacobs and de Lange, 2004; Kim and Sharpless, 2006), it is
the p53-dependent senescence or apoptosis that is thought to mediate the first checkpoint in
telomere-induced tumor suppression.
Inactivation of p53 or Rb can bypass this checkpoint and allow fibroblasts to continue
to proliferate (Hara et al., 1991; Shay et al., 1991). Telomere attrition continues and the
resulting dysfunctional telomeres lead to genomic instability. When the deprotected ends are
recognized as double strand breaks, DNA repair mechanisms, such as non-homologous end
joining (NHEJ) or homologous recombination (HR), are activated to produce fusions with
other chromosomes resulting in a dicentric chromosome. When the dicentric chromosome is
pulled to opposite poles during anaphase, a bridge is formed between the two cells, called an
anaphase bridge. In order for cytokinesis to occur, the anaphase bridge must break to
separate. This break is random and creates amplification in one cell and a corresponding
deletion in the other cell. The new breaks must then be repaired through the same pathways,
resulting in new fusions that will form another bridge and the process repeats. This cycle is
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called the break-fusion-bridge (BFB) cycle and was first noticed by Barbara McClintock
during her studies of maize(McClintock, 1941). Since the sites of breakage and repair are
random, one can see how repeated cycles of BFB triggered by just a few fusions can lead to
changes in the integrity of the genome, either through large losses or amplifications of
genetic information. This rampant genomic instability can lead to the accumulation of
oncogenic changes necessary for a cell to become transformed. Therefore, activation of the
BFB cycle through dysfunctional telomeres represent the second half of the telomere-cancer
paradox: dysfunctional telomere-induced genomic instability can promote tumor formation
(Bailey and Murnane, 2006; DePinho and Polyak, 2004).
While there are many studies associating telomere length to human disease(Jiang et
al., 2007), much of our direct knowledge of in vivo consequences of telomere dysfunction
has come from the telomerase knockout mouse. In this model, gene targeting of the RNA
component of telomerase (mTerc) efficiently disrupts the function of telomerase. However,
owing to the differences in the length of laboratory mouse telomeres (40-80kb) compared to
human telomeres (8-12kb), it takes successive intergenerational breeding of mTerc-/- animals
to reach critical shortening. It is only at later generations (G4 or beyond) that one begins to
see the effects of shortened telomeres(Lee et al., 1998; Rudolph et al., 1999). We sought to
avoid this process by approaching telomere dysfunction from a different angle: targeting the
telomere binding complex, shelterin.

The shelterin complex
The term “dysfunctional telomeres” refers to a state of deprotected telomeres that can
be caused by severe shortening or by uncapping due to disruption of the shelterin
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components(Harrington and Robinson, 2002). Shelterin is composed of six proteins that bind
specifically to telomeres, including: TRF1, TRF2, TIN2, RAP1, TPP1 and POT1(de Lange,
2005) (Figure 3). They are all essential to cell survival, as depletion of shelterin components
either drives cells into cellular senescence or results in early embryonic lethality. Together,
these six proteins form a complex that maintains telomeric length and structure, and protects
chromosome ends from activating the DNA damage response and inappropriate repair
mechanisms. However, each protein plays a unique role in telomere homeostasis.
The two main proteins that anchor the complex to the double stranded telomeric DNA
are telomeric repeat-binding factors 1 and 2 (TRF1 and TRF2), which recognize duplex
TTAGGG repeats and bind directly through their SANT/Myb domain(Broccoli et al., 1997).
Although TRF1 and TRF2 have similar structure and protein binding domains, they recruit
proteins to telomeres differently (Chen et al., 2008) and play distinct roles in protection of
chromosome ends. TRF2 appears to be a vital component of shelterin as its loss is very toxic
to cells. Depletion of TRF2 from cells initiates a potent DNA damage response, which leads
to cellular senescence or very dramatic fusion phenotype indicative of improper activation of
NHEJ (Karlseder et al., 1999; van Steensel et al., 1998). This response suggests that it plays a
prominent role in suppressing both these processes at normal chromosome ends. While the
exact method of repression of these pathways is still speculative, TRF2 has been shown to
interact with other proteins, including the shelterin protein RAP1 (Li et al., 2000), as well as
a variety of non-shelterin proteins, including ATM, the MRN complex, WRN, BLM, Ku86,
ERCC1/XPF, PARP1 and PARP2 (Palm and de Lange, 2008). Many of these proteins are
involved DNA damage sensing and repair processes, leading to the theory that TRF2
repression of these pathways is mediated by physical interactions with these factors. TRF2
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may also play a role in stabilizing telomere secondary structure as it has been shown to
facilitate t-loop formation in vitro (Stansel et al., 2001).
Although it can also bind double stranded telomeric DNA, TRF1 appears to play a
minor role in repression of damage responses and repair. Its depletion also leads to cellular
senescence(Karlseder et al., 2003; Martinez et al., 2009; Sfeir et al., 2009), but in vitro
experiments show that TRF1 is unable to inhibit end-joining of telomeric substrates(Bae and
Baumann, 2007).

Instead, TRF1 may be more important in regulation of telomere

length(Smogorzewska et al., 2000; van Steensel and de Lange, 1997). It can interact with
non-shelterin telomere factors, including PINX1, Tankyrase 1 and Tankyrase 2(Palm and de
Lange, 2008). These factors can in turn interact with telomerase, suggesting telomere length
regulation involves TRF1 recruitment of these factors to telomeres. There is emerging
evidence that TRF1 may also be important for preventing telomere replication mistakes and
protects telomeres against a fragile-telomere phenotype (Martinez et al., 2009; Sfeir et al.,
2009).
The TRF1-interacting nuclear protein 2 (TIN2) has been called the linchpin of
shelterin, as it is able to bind TRF1, TRF2 and TPP1, acting as a bridge between the double
stranded and single stranded telomere binding proteins. While it can stabilize the six protein
complex(O'Connor et al., 2006), TIN2 exists in stoichiometric quantities enough to bind each
molecule of TRF1 or TRF2, suggesting that it may not always bind to both proteins
simultaneously and that the shelterin complex may not always exist with all
components(Takai et al.). It was recently discovered that TIN2 exists in two isoforms in
human cells. One of these isoforms, TIN2L, was shown to bind tightly to nuclear matrix
proteins suggesting a role in anchoring telomeres in the nucleus(Kaminker et al., 2009).
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TIN2
TPP1

TRF1
AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG
-3’
TRF2
POT1
TCCC AATCCC AATCCCAATCCC AATCCCAATCCCAATCCC AATCCC -5’

RAP1

Figure 3: The shelterin complex. Telomeres are bound by a complex of telomere
specific proteins called shelterin, which includes TRF1, TRF2, TIN2, TPP1, POT1
and RAP1. TRF1 and TRF2 bind directly to duplex telomeric DNA, while POT1
binds to the single stranded G-rich 3’ overhang. TIN2 bridges TRF1 and TRF2, while
connecting POT1 to these molecules through TPP1. RAP2 localizes to telomeres
through its interaction with TRF2.
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TPP1 can interact with TIN2 and POT1, providing the essential link for the
recruitment of POT1 to telomeres(Hockemeyer et al., 2007). As with other members of
shelterin, homozygous loss of TPP1 is incompatible with survival(Kibe et al.). Depletion of
TPP1 through genetic ablation(Kibe et al.), RNA interference(Guo et al., 2007), or a mutant
that abolishes POT1 interaction(Guo et al., 2007) leads to cellular consequences consistent
with POT1 loss, suggesting its main role is the recruitment of POT1 to the chromosome ends.
TPP1 can also interact with telomerase, suggesting that it may play role in telomere length
maintenance(Xin et al., 2007).
Originally discovered in S. pombe, protection of telomeres (POT1) is the component
that specifically binds to the single stranded G-rich overhang. It was found based on its
similarity to the ciliate telomere binding protein TEBPα(Baumann and Cech, 2001). It is
essential for the protection of telomeres in yeast as its loss leads to cell death, where the only
surviving colonies have circularized their chromosomes eliminating the need for telomere
protection(Baumann and Cech, 2001). It is one of the most highly conserved members of
shelterin and has been studied in humans, chicken, mice, yeast and plants(Churikov and
Price, 2008; He et al., 2006; Hockemeyer et al., 2006; Hockemeyer et al., 2007; Loayza and
De Lange, 2003; Wang et al., 2007). All POT1 proteins have two highly conserved
oligonucleotide/oligosaccharide binding folds (OB folds) that show specificity for telomeric
sequences and are essential for binding the single stranded 3’ overhang. Human POT1
associates with the rest of the shelterin complex through its interaction with TPP1, an
interaction that appears essential for its function(Hockemeyer et al., 2007). It is also a vital
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component in telomere protection as knockdown of POT1 also triggers a chromosomal
aberrations and cell death(Wu et al., 2006).
Mice have two orthologs of the gene, named Pot1a and Pot1b(Hockemeyer et al.,
2006; Wu et al., 2006). Pot1a is essential to cells as targeted deletion of this gene in the
mouse leads to embryonic lethality very early during development (Hockemeyer et al., 2006;
Wu et al., 2006). Pot1a is necessary for chromosomal end protection as deletion of Pot1a in
murine embryonic fibroblasts (MEFs) promotes chromosomal fusions and a DNA damage
response resulting in cellular senescence(Wu et al., 2006). On the other hand, Pot1b is not
essential for survival as Pot1b-/- mice are viable, and its deficiency in cells does not produce
as severe of a phenotype as loss of Pot1a alone or deletion of both Pot1a and Pot1b(He et al.,
2006; Hockemeyer et al., 2006). Recent studies have implicated Pot1b in telomeric length
maintenance; in particular, the regulation of C-strand resection for the formation of the 3’
overhang, which is greatly elongated following Pot1b loss(He et al., 2006; Hockemeyer et
al., 2006; Hockemeyer et al., 2008).
RAP1 is one of the most evolutionarily conserved members of shelterin. However, its
role in telomere biology seems to vary between species. For instance, in S. cerevisiae, rap1
binds directly to telomeric sequences, where it is involved in the negative regulation of
telomere length, inhibition of fusions, and the recruitment of Sir proteins for silencing of
genes near the telomeric region (Hardy et al., 1992). However, in mammalian cells, RAP1
cannot bind telomeric DNA and depends on TRF2 binding for recruitment to chromosome
ends(Li et al., 2000). Biochemical assays have revealed that the TRF2/RAP1 complex can
inhibit NHEJ-mediated fusions at telomeric ends(Bae and Baumann, 2007), but because of
this dependence, the role of RAP1 alone remains unclear. In vitro studies in human cell lines
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suggest overexpression of RAP1 may have an effect on telomere length regulation, which is
independent of its ability to localize to telomeres(Li and de Lange, 2003). Recent generation
of a fusion protein between RAP1 and the telomeric binding domain of a yeast protein
allowed localization of RAP1 to telomeres independent of TRF2 binding(Sarthy et al., 2009).
Using this fusion protein, localization of RAP1 to telomeres did not prevent DNA damage
signaling, but was sufficient to inhibit NHEJ(Sarthy et al., 2009) suggesting that RAP1 plays
more of a role in repression of repair rather that damage sensing.

How shelterin protects telomeres
The linear nature of eukaryotic chromosomes presents a difficult problem for cells:
how can cellular DNA damage response machinery distinguish the normal ends of
chromosomes from sites of DNA breaks? Or alternatively, how can chromosomes mask its
ends from activating this response so that cells can propagate? This obstacle has been
deemed the “end protection problem”(de Lange, 2009). Telomeres function to solve this
problem, and as discussed above, severe erosion of telomeres exposes chromosome ends to a
potent DNA damage response(d'Adda di Fagagna et al., 2003; Gire et al., 2004), resulting in
p53-dependent senescence or apoptosis (Figure 4).
The role shelterin proteins play in suppressing this response at normal telomeres has
been teased out through the use of mouse embryonic fibroblasts (MEFs) with genetic
ablation of various combinations of these factors. First, TRF2 knockdown experiments show
that cells respond to loss of TRF2 in a similar manner as IR-induced DSB, with the MRN
complex required for the initial sensing of damage at dysfunctional telomeres(Deng et al.,
2009; Dimitrova and de Lange, 2009), while ATM is necessary for propagation of the
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signal(Denchi and de Lange, 2007; Guo et al., 2007). On the other hand, TPP1 or Pot1a/b
disruption leads to a response that is dependent on the ATR pathway (Denchi and de Lange,
2007; Guo et al., 2007). These results reveal that TRF2 acts mainly to repress ATM-mediated
DNA damage responses, while Pot1a and Pot1b are involved in repression of the ATR
pathway (Figure 4). How TRF2 and POT1 act to inhibit these pathways is still unclear.
Paradoxically, many components of DDR pathways can be found normally at telomeres
without activating an apparent DNA damage response(Verdun et al., 2005). Given that TRF2
can interact with these non-shelterin telomeric factors, perhaps it directly suppresses their
activation through physical inhibition. In fact, there is some evidence that the TRF2
interaction with ATM directly inhibit its activity(Karlseder et al., 2004). However, POT1
proteins are not known to interact with non-shelterin components. Instead, it is postulated
that the binding of the POT1 proteins to the 3’ overhang provides protection through
competitive blockade of RPA binding to the single stranded protrusion, preventing the
activation of the ATR pathway (Zou and Elledge, 2003).

Targeted deletion of Pot1a to model telomere dysfunction in vivo
Given the similarities the consequences of disruption of shelterin components have to
severe telomere attrition (Figure 4), we decided to target Pot1a in this project to study
telomere dysfunction in vivo. With the parallels seen between the responses of both types of
dysfunctional telomeres, we believe that the in vivo consequences of loss of Pot1a will also
mimic that of mice with critically short telomeres. We used the conditional Pot1a knockout
mouse(Wu et al., 2006) to allow us to take advantage of the different models of tissuespecific expression of the Cre recombinase to focus on the affect of telomere dysfunction on
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Figure 4. Consequences of telomere dysfunction. Work in human and mouse
cells, as well as the telomerase null mouse models, have shown that telomere
dysfunction caused by severe telomere shortening activates a DNA damage
response (DDR) mainly mediated by the ATM/ATR pathway, which ultimately
leads to p53-dependent apoptosis or senescence. Recent studies in mouse cells
have shown that telomere dysfunction due to uncapping through loss of the
shelterin proteins activate a similar response resulting in p53 activation and
cellular senescence or apoptosis. TRF2 mainly suppresses an ATM-dependent
response, while POT1 protects against ATR-dependent DDR.
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one organ system at a time. This reduces the possibility of confounding factors that may arise
with telomere dysfunction throughout the organism, such as the hematopoietic compromise
that affects late generation telomerase null mice(Lee et al., 1998; Rudolph et al., 1999). In
this project, we focused on the gastrointestinal system, which, as one of the body’s most
proliferative compartments, telomere dysfunction is postulated to play a role due to the
multiple rounds of cell division necessary to maintain the level of tissue renewal.
Similar to results seen in cell culture experiments, our mice show that intestinal
deletion of Pot1a leads to a DNA damage response in cells of the crypts of Lieberkuhn,
which activates p53 leading to upregulation of p21 and increased apoptosis. These
phenotypes are also seen in the gut of late generation telomerase null mice with severe
telomere shortening(Rudolph et al., 1999). Loss of Pot1a in the background of p53 deficiency
results in increased aberrant homologous recombination at telomeres and elevated genomic
instability, which allows Pot1a-/-, p53-/- MEFs to form tumors when injected into SCID
mice(Wu et al., 2006). Similarly, mice with combined Pot1a and p53 formed tumors in the
small intestines and colon. The mouse model produced invasive adenocarcinomas with low
multiplicity, long latency, but high penetrance. Analysis of these tumors showed complex
genomes with heterogeneity in genetic alterations between tumors, indicative of genomic
instability. Taken together, the data we present here demonstrate that intestinal deletion of
Pot1a and p53 produced a mouse model sporadic gastrointestinal cancer driven by telomereinduced genomic instability.
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RESULTS

GENERATION OF A MOUSE MODEL OF TELOMERE-DYSFUNCTION IN THE
GASTROINTESTINAL TRACT THROUGH LOSS OF POT1A
Generation and validation of the Villin-Cre Pot1a mouse colony
Since homozygous loss of Pot1a leads to embryonic lethality, we used a conditional
knockout mouse previously created in our lab, in which exons 4 and 5 of the Pot1a gene are
flanked by loxP sites(Wu et al., 2006). Exon 4 contains the translational start site and exon 5
contains part of the first OB-fold. The gastrointestinal tract was targeted by crossing the
conditional Pot1a mouse with a Villin-Cre (VCre) transgenic mouse, which specifically
expresses the Cre recombinase in intestinal epithelia through the Villin promoter(Madison et
al., 2002). These mice were mated to produce the three cohorts used for this study (Table 1):
one group which does not possess the VCre transgene and should therefore have wild-type
Pot1a in the intestines (VCre-); one consisting of VCre+ Pot1a+/+ or Pot1aF/+mice, which
express the Cre recombinase, but retain one or both wild-type alleles of Pot1a in the
intestines (VCre+); and the mutant cohort of VCre+ Pot1aF/F mice with both copies of Pot1a
deleted in the intestines (Pot1aint∆). A mating set-up between VCre- Pot1aF/+ and VCre+
Pot1aF/+ revealed that Pot1aint∆ are viable and born at expected Mendelian ratio (Table 1).
Cre-mediated deletion of the Pot1a allele was determined indirectly through several different
methods. First, we developed a PCR strategy that is able to detect the recombination event in
which exons 4 and 5 are deleted. This method can distinguish between this “delta” allele and
the intact “floxed” conditional allele (Figure 5A). Genomic DNA was isolated from various
tissue samples harvested from Pot1aint∆ mice and assayed for the presence of the delta band.
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Table 1: Cohorts for study in the Villin-Cre, Pot1a colony and progeny distribution.
The table below lists the three main cohorts studied and the genotypes included in those
cohorts. Results from a VCre- Pot1aF/+ x VCre+ Pot1aF/+ cross show that mice with
homozygous deletion of Pot1a in the intestines (VCre+ Pot1aF/F) are viable and observed in
approximately the expected Mendelian ratios.

Cohort name

VCre-

Genotypes included

Expected

Observed

VCre- Pot1a+/+

1/8 (12.5%)

14 (13.2%)

VCre- Pot1aF/+

1/4 (25%)

25 (23.5%)

VCre- Pot1aF/F

1/8 (12.5%)

13 (12.3%)

*VCre+ Pot1a+/+

1/8 (12.5%)

12 (11.3%)

*VCre+ Pot1aF/+

1/4 (25%)

27 (25.4%)

VCre+ Pot1aF/F

1/8 (12.5%)

15 (14.1%)

Total:

106 mice

VCre+

Pot1aint∆

* These two cohorts of mice behave very similarly since heterozygous loss of Pot1a has no
apparent affect on cells in vitro or in vivo.
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Figure 5: Pot1a deletion is restricted to the intestines. Panel A shows the PCR
strategy for detecting Pot1a deletion from genomic PCR. Primers 1 & 3 are used to
detect the null allele. Primers 2 & 3 are used to distinguish the floxed allele vs. the WT
allele, and serve as an internal control for the PCR reaction. DNA was extracted from
several different organs from a Pot1aint∆ mouse. PCR analysis shows that the ∆Pot1a
band is only amplified in genomic DNA harvested from the small intestine, cecum and
colon; and not in other organs, including the stomach (Panel B).
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The Villin-Cre transgene is only active in the intestinal epithelial cells and not in other
tissues, including the liver and stomach(Madison et al., 2002). Accordingly, PCR results
showed that the delta band was only amplified in samples harvested from the small intestine,
cecum and colon, but not the stomach, kidney, liver, heart or spleen (Figure 5B). These
results confirm that deletion of Pot1a occurs preferentially in the gastrointestinal tract.
To measure the expression of Pot1a mRNA, RT-PCR was performed using a Taqman
Gene Expression Assay with probes specific for a region located in exon 4 of the Pot1a gene.
RNA was isolated from liver tissue and scrapings of epithelial cells from the small intestine
and colon. Analysis of tissues from VCre+ Pot1aF/+ mice demonstrated that loss of one allele
of Pot1a leads to approximately 30% reduction in Pot1a expression in both the small intestine
(0.720±0.046, t-test, p = 0.022) and colon (0.69±0.096, t-test, p = 0.012) (Figure 6).
Intestines with both alleles of Pot1a deleted (Pot1aint∆ ) showed only a tenth of the expression
seen in VCre- control small intestines (0.120±0.072, t-test, p<0.001) and colon (0.183±0.104,
t-test, p<0.001) (Figure 6). These results confirm that conditional deletion of both Pot1a
alleles leads to a dramatic reduction in Pot1a mRNA expression that is restricted to the small
intestines and colon.
Finally, to determine the distribution of the Cre-mediated deletion, we crossed VCre,
Pot1a mice with the Rosa26-LacZ reporter (R26R) strain(Soriano, 1999) to generate mice of
all the genotypes of the above cohorts with an additional R26R gene. The R26R transgene
consists of a loxP-flanked neomycin cassette in front of a lacZ reporter gene driven by the
Rosa26 promoter, which under normal conditions is not expressed(Soriano, 1999). In the
presence of Cre recombinase, the neomycin cassette is removed, allowing for expression of
the reporter transgene. Tissue from the various cohorts produced in this mating were
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Figure 6: Villin-Cre expression leads to decreased expression of Pot1a mRNA in
the intestines. RNA was extracted from liver tissue and intestinal scrapings from
animals in the three cohorts. mRNA expression was analyzed through RT-PCR using
Taqman probes specific for a region in exon 4 of the Pot1a gene. The above results
show that animals with no VCre transgene (VCre-) did not show any changes in Pot1a
expression. The VCre transgene in a Pot1aF/+ animal leads to a slight decrease in Pot1a
expression in both the small intestine and the colon, but not in the liver. The
expression of Pot1a is drastically decreased when both copies of Pot1a are deleted
(Pot1aint∆). (*: p-value = 0.022; **: p-value = 0.012; ***: p-value <0.001) Tissue
samples from three animals for each genotype were analyzed. RT-PCR reactions were
performed in triplicate and normalized to GAPDH expression.
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harvested and assayed for X-gal staining, which is an indicator of the lacZ gene expression
leading to β-galactosidase (β-gal) activity. X-gal staining was only observed in mice that
contained both the reporter transgene (R26R+) and the Villin-Cre transgene (VCre+) (Figure
7). Furthermore, in VCre+ R26R+ animals, blue staining was only seen the small intestines
and colon, while other tissues, such as the kidney, heart, liver and stomach remained
unstained (Figure 8).
Closer inspection revealed that β−gal activity was restricted to the epithelial cells of
the GI tract, leaving the supporting stroma and muscularis mucosa unstained (Figure 8).
Interestingly, Pot1aint∆ intestines showed a decrease in staining intensity in both the small
intestines and colon when compared to VCre+ controls, with some crypts completely devoid
of X-gal staining (Figure 8, arrows). This suggests that VCre activity and as a result Pot1a
deletion may not be complete in Pot1aint∆ intestines.

Pot1aint∆∆ mice have normal intestinal morphology, but increased apoptosis and
anaphase bridges
Mice in the VCre, Pot1a colony were followed for up to 2 years. The majority of
these mice lived up to two years without overt signs of illness suggesting that loss of Pot1a in
the intestinal epithelium does not affect overall survival. Accordingly, Kaplan-Meier analysis
of survival showed that lifespan was not significantly affected by Pot1a deletion (Figure 9).
Late generation telomerase null mice with critically shortened telomeres show degenerative
phenotypes in the intestines, such as villous blunting and crypt atrophy, which lead to weight
loss (Begus-Nahrmann et al., 2009; Rudolph et al., 1999). To determine if loss of Pot1a also
results in these features, intestines were harvested from three month old animals and
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Figure 7: β -galactosidase activity is only detected in the intestines when both the
Rosa26-LacZ (R26R) and the Villin-Cre (VCre) transgenes are present. To
determine the distribution of Villin-Cre expression and indirectly determine where
Pot1a is being deleted, mice from the VCre, Pot1a colony were crossed with the
Rosa26-LacZ (R26R) reporter transgene. Cre recombinase activity activates the
reporter gene, which can be detected through β-galactosidase (β-gal) activity.
Intestines were collected from animals of various genotypes and assayed for β-gal
activity. Positive activity is indicated by blue staining. Intestines that did not express
the VCre transgene (VCre-) and mice that were R26R negative did not show any β gal
activity. In contrast, VCre+ R26R+ mice showed β-gal activity in both the small
intestines and colons. Two animals were examined per genotype.
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Figure 8: Villin-Cre activity is specific to the intestinal epithelium. β-gal activity
was assayed in various organs of VCre+ Rosa+ mice. No activity was seen in the heart,
kidney, liver or stomach of these animals. However, β-gal staining was readily visible
in the small intestines and colon. Note that the staining in the Pot1aint∆ Rosa26+
intestines is less intense than in the control samples. Furthermore, there seem to be
entire crypts that do not stain for β-gal at all (arrow). These results suggest that
intestinal deletion of Pot1a may not be complete in the Pot1aint∆ animals. (Two
animals for each genotype were examined.)
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examined. Comparison of hematoxylin and eosin (H&E) stained sections from Pot1aint∆
intestines to controls showed no villous blunting, no crypt atrophy, and no changes to the
overall morphology of the intestines (Figure 10).
However, closer inspection revealed an increase in apoptotic cells in the crypts of
Lieberkuhn (Figure 10), a characteristic that is seen in mice with telomere
dysfunction(Begus-Nahrmann et al., 2009; Cosme-Blanco et al., 2007; Wong et al., 2000).
Examination of 500 crypts per sample, comparing four animals per genotype, showed that
there was an 8-fold increase in apoptotic bodies in the Pot1aint∆ animals compared to the
VCre- controls (control: 0.076±0.057 vs. Pot1aint∆: 0.598±0.119, p = 0.001) (Figure 10).
There was no significant difference between the VCre- and VCre+ controls, suggesting that
the phenotype is due to Pot1a deficiency and not Villin-Cre expression. TUNEL staining was
also performed to assay for apoptosis. Four animals per genotype were tested and 500 crypts
per animal were examined. Quantification of TUNEL positive cells in the crypts revealed a
15-fold increase in the intestines of Pot1aint∆ animals compared to the VCre- controls
(control: 0.076±0.072 vs. Pot1aint∆: 1.22±0.08, p = 0.001) (Figure 11).
Dysfunctional telomeres can be improperly repaired by the generation of random
fusions through the non-homologous ending joining (NHEJ) or homologous recombination
(HR) pathway forming dicentric chromosomes. During anaphase, migration of the dicentric
chromosomes to opposite poles can be seen as an anaphase bridge. These are readily visible
in H&E sections and are used as an indication of telomere dysfunction in highly proliferative
compartments, including the intestinal epithelium (Cosme-Blanco et al., 2007; Rudolph et al.,
2001). To determine if Pot1a deletion leads to telomere dysfunction in our model, H&E
sections were examined for anaphase bridges (Figure 12). The number anaphase bridges
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Figure 9: Intestinal deficiency of Pot1a does not affect overall survival. Mice in
the VCre, Pot1a colony were followed for up to 2 years. Kaplan-Meier analysis of the
cohorts show that Pot1aint∆ mice survived at a rate comparable to controls.
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Figure 10: Loss of Pot1a does not affect the gross morphology of the intestinal
epithelial, but increases apoptosis in crypts. Examination of H&E staining of
intestines from 1-year old VCre, Pot1a animals showed that there is no appreciable
difference in gross morphology. Closer examination of the intestinal crypts revealed
that Pot1aint∆ animals have an increase in apoptotic bodies. Quantification showed
that there is 8-fold increase in apoptotic bodies in the Pot1aint∆ compared to the VCrecontrols (0.076±0.057 vs. 0.598±0.119, p = 0.001). Intestines from four animals per
genotype were examined, and 500 crypts per animal were analyzed.
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Figure 11: Pot1a deficiency leads to increased TUNEL positive cells in the
intestinal crypts. TUNEL was performed on intestinal samples to detect apoptosis.
TUNEL positive cells (arrows) were only detected in the intestines of Pot1aint∆
animals. Furthermore, the increase in TUNEL positive cells was restricted to the
crypts. No appreciable increase was seen in the villi. Intestines from four animals per
genotype were examined, and 500 crypts per animal were analyzed.
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Figure 12: Anaphase bridges are a hallmark of telomere dysfunction.
Dysfunctional telomeres can lead to chromosomal fusions that can be visualized as
anaphase bridges. The upper panel shows a normal anaphase (single arrow) and
several examples of anaphase bridging (double-line arrows). Quantification of the
anaphase bridges in Pot1aint∆ mice show a 2.5 fold increase in ABI as compared to
VCre- (0.258±0.008 vs. 0.093±0.023). Intestines from four animals per genotype were
examined, and 500 crypts per animal were analyzed.
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observed was divided by the total number of anaphase seen to determine the anaphase bridge
index (ABI). Quantification of the anaphase bridges in Pot1aint∆ mice show a 2.5 fold
increase in ABI as compared to VCre- (0.258±0.008 vs. 0.093±0.023, respectively; p=0.002)
(Figure 12).
Taken together, these results indicate that while Pot1aint∆ mice do not show the same
overt intestinal degeneration, Pot1a deficiency leads to phenotypes in the crypts of
Lieberkuhn that recapitulate those observed in telomerase null animals with critically
shortened telomeres, including increased apoptosis and anaphase bridges.

Pot1a deficiency leads to increased activation of p53 and p21
Similar to severe telomere attrition, loss of Pot1a activates a potent DNA damage
response that triggers p53-dependent cellular senescence in cell culture(Wu et al., 2006). p53
is also a potent inducer of apoptosis in mouse models of telomere shortening(Chin et al.,
1999). To determine if loss of Pot1a also activates p53 in our model, IHC was performed on
paraffin-embedded intestine sections (Figure 13). Comparison of four animals per genotype
and 500 crypts per animal revealed that intestines from Pot1aint∆ mice show a 10-fold
increase in p53 positive cells as compared to VCre- controls (Pot1aint∆, 0.362±0.068; VCre-:
0.003±0.0008; t-test, p=0.006). In fact, little to no p53 staining was seen in either VCre- or
VCre+ controls, again confirming that these phenotypes are due to loss of Pot1a instead of
Villin-Cre expression.
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Figure 13: Loss of Pot1a activates p53 in the intestinal crypts. p53 is a major
mediator of apoptosis that is also activated in response to telomere dysfunction. IHC
staining for p53 was performed to determine if this response could be observed. Cells
staining positively for p53 (arrows) were seen almost exclusively in the intestinal
crypts of the Pot1aint∆ mice. Intestines from four animals per genotype were examined,
and 500 crypts per animal were analyzed.
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p21 is potent inducer of cell cycle arrest during cellular senescence triggered by
telomere attrition(Herbig et al., 2004) and Pot1a loss in cultured cells (Wu et al., 2006). p21
is also a downstream target of p53 that is also activated in response to telomere dysfunction
in late generation telomerase null mice(Choudhury et al., 2007). IHC to assay for p21
expression was performed to determine if the increased expression of p53 seen above also
leads to upregulation of p21 (Figure 14). Indeed, intestines from Pot1aint∆ mice show an 8fold increase in p21 expression over VCre- controls (3.98±1.08 vs. 0.54±0.15, respectively; ttest; p = 0.006). Four mice from each cohort were examined and 500 crypts from each
sample were analyzed.
These results indicate that Pot1a deficiency leads to the activation of p53 and its
downstream effector, p21. Taken together with the previous section, these data suggest that
loss of Pot1a activates p53 leading to apoptosis or p21 activation and senescence, similar to
cells and mice with severe telomere attrition or Pot1a deficient cells (Figure 4).

Loss of Pot1a leads to activation of a telomere-induced DNA damage response
Pot1a binds to the single-stranded G-rich telomeric overhang to protect it from
activating a DNA damage response mediated by ATR(Denchi and de Lange, 2007; Guo et
al., 2007). Loss of Pot1a is thought to expose the overhang to RPA binding, which recruits
ATR/ATRIP. These proteins trigger the DDR pathway by phosphorylating and recruiting
factors like the phosphorylated histone variant H2AX (γ-H2AX), the mediator of DNA
damage checkpoint1 (MDC1), and p53 binding protein 1 (53BP1)(Shiloh, 2003). These
proteins accumulate at the sites of damage and along the surrounding chromatin, and can be
readily visualized through fluorescence microscopy as DNA damage foci. To assess damage
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Figure 14: Loss of Pot1a leads to upregulated p21 expression in the
intestines. p21 is a downstream target of p53 and is thought to be involved in
triggering senescence in response to telomere dysfunction. IHC of intestinal
sections show an increase in p21 positive nuclei (arrows) in Pot1aint∆ crypts.
Quantification (graph) reveals almost an 8-fold increase in p21 expression in
mice that have lost Pot1a. Intestines from four animals per genotype were
examined, and 500 crypts per animal were analyzed.
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signaling at telomeres, an invaluable experimental tool based on this property has been used
extensively. Telomere-induced damage foci (TIFs)(Takai et al., 2003) are fluorescentlylabeled DNA damage protein markers, such as γ-H2AX or 53BP1, that co-localize to
dysfunctional telomeres, which are also marked by fluorescently-labeled telomeric nucleotide
probes or shelterin proteins. We assayed for TIFs in paraffin-embedded tissues through
double immunofluorescent staining for γ-H2AX (green) and the telomere binding protein,
mTRF2 (red) (Figure 15). Sections were examined through fluorescence or confocal
microscopy. Nuclei with three or more co-localized foci were scored as TIF positive.
Examination of intestinal sectionals revealed that TIF positive cells were found exclusively
in the crypts of Lieberkuhn; no TIFs were seen in the villi (Figure 16). Comparison of the
different cohorts showed that TIF positive cells were found mostly in Pot1aint∆ crypts, which
had 10-fold more TIF positive cells than VCre- controls (26.4 ± 7.4 vs. 2.2 ± 0.8 TIF positive
cells per 100 nuclei, respectively; t-test; p=0.005). These results indicate that deletion of
Pot1a elicits a DNA damage response in the intestinal crypts.

Intestinal Pot1a deficiency does not affect response to gamma-irradiation
The results above have shown that loss of Pot1a induces a DNA damage response in
the intestinal epithelium leading to increased cell cycle arrest and apoptosis. Although these
features do not appear to lead to degenerative phenotypes, we postulated that chronic DNA
damage may have an effect on the stem cell reserve of the intestines. To determine whether
this mechanism of telomere dysfunction has an effect on the regenerative capacity of the
intestines, we subjected mice in the Villin-Cre, Pot1a colony to whole body gamma
irradiation (IR), which would deplete the epithelial layer.
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Figure 15: Loss of Pot1a activates a DNA damage response in the intestines.
Telomere-induced damage foci (TIFs) are formed when markers of DNA damage,
such as γ-H2AX (green) colocalize to sites of dysfunctional telomeres (marked by
mTRF2 (red)). Cells with three or more foci are considered TIF positive. Double IF
staining of intestinal sections demonstrate that Pot1aint∆ crypts contain ten-fold more
TIF positive cells than controls. Intestinal crypts from four animals per genotype
were examined, and 1000 nuclei per animal were analyzed.
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Figure 16: DNA damage is only observed in cells of the crypts. Double IF staining
of intestinal sections to assay for telomere-induced damage foci (TIFs). γ-H2AX
serves as a marker of DNA damage (green), while mTRF2 serves as a marker for
telomeres (red). The left panel shows pictures of a villus, while the right panel shows
crypts. Several TIF positive cells are indicated by white arrow.
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In the first experiment, two groups of 10-week old mice were subjected to whole
body IR. At a dose 4Gy, there seemed to be no difference between the responses of the two
genotypes as all the animals survived more than 40 days (Figure 17, solid lines). Next, we
increased the dose and exposed a second set of 10-week old animals to a higher dose of
radiation (8Gy). This dose proved to be lethal as animals in both cohorts did not survive for
more than three weeks after exposure. A comparison of the survival curves showed that there
was no significant difference between survival among animals that were deficient in Pot1a
compared to wild-type (Figure 17, dashed lines).
One possible reason for the lack of difference may be the age of the mice. Despite the
increased apoptosis that would put a strain on stem cell reserve, perhaps the intestines of 10week old animals have not been challenged enough by the telomere dysfunction to
significantly deplete the reserve of such a proliferative organ. The experiment was repeated
in animals that were aged to one year. These mice were exposed to a 6Gy dose of radiation.
Similar to previous results with a 4Gy dose, all the animals survived longer than 40 days
(Figure 18A). Surprisingly, comparison of the intestinal morphology of animals at one and
four days after radiation exposure also did not show any significant difference (Figure 18B).
These results suggest that the Pot1aint∆ mice responded to radiation in a similar fashion as the
wild-type controls.

Discussion
We sought to create a mouse model of telomere dysfunction in the gastrointestinal
tract through the targeted deletion of Pot1a. To achieve this, we crossed a conditional Pot1a
knockout mouse with the Villin-Cre transgenic mouse that only expresses the Cre
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Figure 17: Pot1a deficiency in the intestines does not affect survival of 3-month
old animals after irradiation. Whole body irradiation was given at a dose of 4Gy to
3-month old animals. The treatment did not affect survival of control or Pot1aint∆ mice
(solid lines) as they all survived for over 40 days. When the dose was increased to
8Gy, none of the irradiated animals survived longer than 3 weeks. However, there was
no significant difference between the survival of the Pot1aint∆ mice as compared to
control mice (dashed lines).
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Figure 18: Pot1a deficiency does not affect intestinal response to irradiation. One
year old animals were exposed to 6Gy of γ-irradiation (n=6 for both groups). All
animals survived at least 40 weeks (Panel A). Intestines of one year old mice exposed
to 6Gy doses of irradiation were examined one and four days after treatment (Panel
B). Surprisingly, analysis of H&E staining shows little effect on the intestines at both
time points, irrespective of Pot1a status.
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recombinase in the GI tract. Our data show that despite the fact that loss of Pot1a in cell
culture is toxic, leading to cellular senescence, mice with homozygous loss of Pot1a in the
intestines (Pot1aint∆) were viable and born at expected the expected Mendelian ratios. Pot1a
deletion was verified indirectly through genomic PCR. However, the appearance of the delta
band did not correlate with the disappearance of the floxed band. This result may be
explained by the fact that Villin-Cre is only expressed in the epithelial layer, as demonstrated
by the X-gal staining. There are many different cell types in the intestines in addition to the
epithelial layer, including the surrounding stromal cells that support the epithelium,
endothelial cells that make up the capillaries and lymphatic vessel in each villus, and
lymphocytes. Although intestinal scrapings were performed to enrich epithelial cells from the
supporting submucosa and muscle wall, these other cells could not be separated and may
contribute to the amplification of the flox band.
Interestingly, X-gal staining in VCre, Pot1a, R26R+ mice demonstrated that Cre
activity was restricted to intestinal epithelial cells. However, qualitative comparisons of
staining suggested that β-gal activity was not equal in Pot1aint∆ R26R+ mice as compared to
VCre+ R26R+ controls. The staining was in fact weaker throughout the crypt-villus axis in
Pot1aint∆ intestines, and some crypts did not stain for X-gal at all. This result may prove to be
significant as it suggests that Pot1a may not be completely deleted in these intestines.
The VCre, Pot1a colony was followed for over two years, and there was no difference
in overall survival between mice with Pot1a loss and controls. Comparison of intestinal
morphology also revealed no appreciable difference in gross morphology. However, closer
examination revealed that loss of Pot1a leads to various microscopic changes in the intestinal
epithelium. Pot1a deletion leads to increased apoptotic cells in the crypts, as well as
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upregulation of p53 and p21 expression. Finally, Pot1a deletion leads to increased cells with
TIFs, an indicator of activation of the DDR in response to dysfunctional telomeres. These
data correspond to previous work in cell culture, which has shown that deletion of Pot1a
leads to a DNA damage response, which activates p53 to trigger cell cycle arrest through p21
or apoptosis(Wu et al., 2006). Late generation telomerase null animals with critically short
telomeres have also shown the same features in intestinal crypts(Choudhury et al., 2007;
Rudolph et al., 1999). Taken together, we have generated a model of telomere dysfunction
through Pot1a disruption in the gastrointestinal tract that has similar microscopic features as
mouse models of telomere attrition.
However, our model does not show the overall morphological features of critical
telomere shortening, such as blunting or atrophy of villi(Rudolph et al., 1999). The β-gal
staining result on the reporter mice may provide some insight to this result. Given the
apoptosis results, one possible explanation is that Pot1a deficient cells are being culled from
the crypts through p53-dependent apoptosis, while the cells that have retained some Pot1a
expression due to incomplete deletion of the two conditional alleles or complete inactivation
of the Cre recombinase are populating the villi. This phenotype has been described
previously in mice that have intestinal specific Mdm2-deficiency(Valentin-Vega et al.,
2008). Mdm2 is a potent inhibitor of p53, and its loss in mice leads to p53-dependent
apoptosis and consequently embryonic lethality(Montes de Oca Luna et al., 1995). Even
conditional deletion of Mdm2 in tissues, such as the heart and nerve cells, cannot produce
viable animals(Grier et al., 2006; Xiong et al., 2006). However, the intestine is able to
compensate for such toxic insults by selecting for cells that have lost the VCre transgene and
have intact Mdm2 activity(Valentin-Vega et al., 2008). It is possible that our model is
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behaving similarly to the Mdm2, with the cells that have lost or reduced Cre expression
surviving to populate the villi and prevent degenerative phenotypes.
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THE EFFECT OF POT1A DEFICIENCY ON ESTABLISHED MOUSE MODELS OF
GI TUMORS
Because of the potent DNA damage response that is elicited in response to Pot1a
deficiency and the subsequent activation of p53, p21 and apoptosis in the intestines of the
VCre, Pot1a animals, we postulate that loss of Pot1a will be tumor suppressive in vivo. The
mTerc null mouse has been used in multiple cancer models to show that critically short
telomeres are tumor suppressive(Cosme-Blanco et al., 2007; Farazi et al., 2003; Feldser and
Greider, 2007; Gonzalez-Suarez et al., 2000; Greenberg et al., 1999; Khoo et al., 2007;
Rudolph et al., 2001; Wong et al., 2003) (Table 2). For example, late generation telomerase
null mice are resistant to skin tumors induced by the DMBA/TPA chemical skin
carcinogenesis model(Gonzalez-Suarez et al., 2000). Also, in the APCmin intestinal
carcinoma mouse model, mice with critically short telomeres showed improved survival with
a decrease in macroscopic adenoma formation compared to mice with intact
telomeres(Rudolph et al., 2001). To determine if loss of Pot1a in the intestines is also tumor
suppressive, we combined our Villin-Cre, Pot1a mouse with two separate models of
intestinal cancer: the APCmin mouse or the chemical colitis-induced model of colorectal
cancer.

The effect of Pot1a-induced telomere dysfunction on the APCmin genetic model of
intestinal tumorigenesis
Mutations in the adenomatous polyposis coli (APC) gene are responsible for
intestinal tumor syndrome called familial adenomatous polyposis (FAP) and found in 34-
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Table 2: Shortened telomeres (Terc-/-) reduce tumor incidence in mouse models of
cancer
Gene or
treatment

Tumor phenotypes Effect of dysfunctional telomeres

APCmin

Multiple intestinal
neoplasia (MIN).

Alb-uPA

hepatocellular
carcinoma (HCC)

decreased number and size of liver nodules. et al. 2003

PMS2

Lymphomas,
sarcomas, and
colon carcinomas

reduced the incidence of all three tumors
types.

Em-myc

Formation of lymphoma was almost
Feldser and
Burkitt’s lymphoma. completely suppressed for two years in mice Greider 2007
with dysfunctional telomeres (G5/G6)

ATM

Thymic lymphoma

increase in (microadenomas)
decreased size and number of
macroadenomas

Ref.
Rudolph, Millard
et al. 2001

Farazi, Glickman

Siegl-Cachedenier,
Munoz et al. 2007

Delayed onset and decreased incidence of
thymic lymphomas

Qi, Strong et al.
2003; Wong,
Maser et al. 2003

Squamous cell
DMBA/TPA
carcinomas (SCC)
Treatment
of the skin

Decreased growth rate and size of
papillomas, with a slight decrease in
numbers. G5 mice with dysfunctional
telomeres were almost completely
Resistant to papilloma formation.

(Gonzalez-Suarez,
Samper et al.
2000)

CCl4 or DEN Hepatocellular
carcinoma (HCC)
treatment

Decreased number and size of liver nodules. et al. 2003)

(Farazi, Glickman
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72% of sporadic colorectal cancer(Takayama et al., 2006). In the APCmin mouse model, loss
of the wildtype copy of the APC allele results in mice with multiple intestinal neoplasia, at
100% penetrance. Previous results from the mTerc-/-, APCmin mouse, showed that critically
short telomeres improved overall survival of these mice by suppressing the progression of
microadenoma to macroadenoma, and impairment of macroadenoma growth(Rudolph et al.,
2001). This is thought to be due to telomere-induced p53-dependent apoptosis or senescence,
as the anaphase bridge index, p53 staining and apoptotic index is all increased in the late
generation mutant mice(Rudolph et al., 2001). To determine if telomere dysfunction due to
loss of Pot1a will have the same effect, the Villin-Cre, Pot1a mice were crossed with the
APCmin mice to produce the following three cohorts: VCre- APCmin, VCre+ APCmin, and
Pot1aint∆ APCmin.
These mice were followed and monitored for signs of intestinal tumor burden,
including abdominal distention, anemia, cachexia and rectal prolapse. Moribund animals
were euthanized and intestines were harvested and examined. Tumors were mostly round
sessile adenomas, and the size (longest dimension) and number were noted. Animals
developed between 29 and 76 tumors, and ranged in size from 1mm to 6mm. To simplify
quantitation, tumors were divided into three size categories: less than 2mm, 2-4mm, and
greater than 4 mm. Comparison of the three cohorts revealed that there was no significant
difference in the number of tumors formed in each size category, nor in the total number of
found (Figure 19, Table 3). These results suggest that unlike late generation telomerase null
mice, Pot1a deficiency is not tumor suppressive.
Since telomere dysfunction due to Pot1a loss did not affect tumor formation, we
examined the histological features of the tumors formed in each cohort to determine if there
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Tumor distribution in VCre, Pot1a, APC cohorts
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Figure 19: Loss of Pot1a does not affect the number or size of tumors in APCmin.
The number and size of tumors found in the intestines of mice from the various Pot1a,
APC cohorts were recorded on dissection of moribund animals. Tumors from the
small intestine were divided into three size categories, while the few colon tumors that
formed were lumped together. Comparison of the cohorts revealed no significant
difference between the total number or predominant sizes of tumors found in each
cohort.
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Table 3: Summary of average tumors burdens for each cohort
Cohort/
Tumor size

VCre- APCmin/+

VCre+ APCmin/+

Pot1aint∆∆
APCmin/+

< 2mm

23.0 ± 14.0

23.5 ± 8.6

27.3 ± 10.4

2 – 4mm

15.2 ± 6.2

22.0 ± 5.6

19.5 ± 11.1

> 4mm

6.7 ± 3.8

11.8 ± 5.1

6.7 ± 3.5

Colon

1.7 ± 1.2

1.5 ± 1.3

1.5 ± 1.5

total

46.5 ± 14.4

58.8 ± 11.4

54.2 ± 18.7
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APCmin

Pot1aint∆ APCmin

Figure 20: Pot1a loss does not affect the tumor type or grade in APCmin mice.
Comparison of H&E staining of intestinal sections from Pot1aint∆ APCmin and APCmin
mice reveal no histological differences between the two groups. Both develop welldifferentiated adenomas with no invasion. Areas of tumors are outlined by red-dashed
line.
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was a difference in the type or grade of tumor formed. H&E staining of paraffin embedded
sections revealed that mice from all three cohorts developed benign well-differentiated
adenomas. There were no signs of invasion or metastasis, and overall no significant
histological difference appreciated between tumors from Pot1aint∆ APCmin mice and controls
(Figure 20). This result suggests that Pot1a deficiency does not affect the grade of tumor that
is formed in the APCmin background.
While Pot1a deficiency did not affect the type and grade of tumor formed, it appeared
to have an effect on overall survival. Kaplan-Meier analysis of overall survival was
performed (Figure 21) and Pot1aint∆ APCmin mice showed a significant reduction in lifespan,
with a median survival of 16.3 weeks and compared to 25 weeks in control VCre- APCmin
mice (t-test, p = 0.0012). This result suggests that loss of Pot1a leads to decreased survival in
the APCmin colony.
Since there was no appreciable difference between the tumor burden for each cohort
at death, we hypothesized that perhaps tumor formation was occurring earlier in Pot1aint∆
APCmin/+ mice. To determine if this was the case, we surveyed five mice from the VCreAPCmin/+ and the Pot1aint∆ APCmin/+cohorts at an early timepoint (12 weeks) for tumor
formation. The number of tumors visualized on dissection was noted and categorized by size
for each animal as described above (Figure 22A). Statistical analysis of each size category
revealed that while the total number of tumors was not significantly increased in Pot1aint∆
APCmin/+ mice, these mice did have larger tumors at earlier timepoints (Figure 22B). These
data suggest that the reason for decreased survival in Pot1aint∆ APCmin/+ mice is that Pot1a
deficiency accelerates tumor formation in the APCmin background.
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Figure 21: Intestinal depletion of Pot1a leads to decreased overall survival in
APCmin mice. The VCre, Pot1a mice were crossed with APCmin mice to determine the
affect of loss of Pot1a on this mouse model of intestinal tumorigenesis. Surprisingly,
Pot1aint∆ APCmin (red line) leads to earlier death than VCre- APCmin controls (black
line), with a median life span of 16.3 weeks vs. 25.0 weeks, respectively. VCre+
controls (blue line) showed no significant difference when compared to VCrecontrols. (n=27 animals for VCre- APCmin; n=12 for VCre+; and n=20 for Pot1aint∆
APCmin.)
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Figure 22: Pot1aint∆∆ APCmin animals form large tumors earlier than control mice.
To determine why Pot1aint∆ APCmin animals died earlier than control mice, five mice
from each cohort were examined for tumor formation at 12 weeks of age. Panel A
shows the number and size of tumors found in each mouse that was examined. Tumors
were mostly round sessile polyps and size was determined by longest dimension. A
statistical comparison of the number of tumors stratified by size showed that
Pot1aint∆ APCmin mice had more medium (2-4mm) and large (>4mm) tumors at 13weeks than control.

- 51 -

To gain some insight as to why tumor formation was accelerated, we examined the
histological features of the 12 week old mice through H&E staining. Comparison of
apoptotic bodies in VCre-, VCre+ and Pot1aint∆ APCmin/+ mice revealed a 7.5-fold increase in
apoptosis in the intestinal crypts of Pot1aint∆ APCmin/+ mice as compared to VCre- APCmin/+
controls (0.75±0.11 vs. 0.10±0.05, respectively; t-test, p>0.001) (Figure 23A). We further
examined the intestines for the presence of anaphase bridges. There was a modest 1.5 fold
increase in anaphase bridge index in the Pot1aint∆ APCmin/+ crypts as compared to controls
(Pot1int∆: 0.017±0.02; VCre-: 0.08±0.02; t-test; p = 0.002) (Figure 23B). The increased
anaphase bridges suggest that there may be increased genomic instability in APCmin
intestines that are deficient in Pot1a, possibly contributing to increased apoptosis.

Discussion
The data described above indicate that our model of Pot1a deficiency is not tumor
suppressive. Instead, telomere dysfunction caused by uncapping appears to accelerate tumor
initiation as evident by the heavier tumor burden in young animals and decreased survival of
the Pot1aint∆ APCmin/+ cohort as compared to VCre- and VCre+ APCmin/+ controls. These
results are in contrast to what was seen in late generation telomerase null mice, where
telomere dysfunction from severely shortened telomeres acted to suppress tumor
formation(Rudolph et al., 2001). This may be due to telomere-induced genomic instability
driving LOH of the APC allele faster than in wild-type controls, as the mutant intestines
show an increase in anaphase bridging. While the concurrent increase in apoptosis may
suggest that tumor suppression should occur, perhaps this increased turnover combined with
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Figure 23: Pot1aint∆∆ APCmin have increased apoptosis and anaphase bridges. Five
mice from each cohort were examined at 12 weeks of age (500 crypts per animals).
(A) Quantification of apoptotic bodies. (B) Quantification of the number of anaphase
bridge index (# anaphase bridges over total anaphases).
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genomic instability shortens the time needed for generation and selection of cells with
cancer-promoting genomes.
The combination of telomere-induced genomic instability with the tumor-initiating
power of the APCmin mutation in the intestinal epithelium, suggests that it might be a good
model for promoting tumor progression. Unfortunately, the accumulation of the appropriate
genetic alterations to promote progression is a stochastic process that requires time. The
overwhelming tumor burden of this model prevented the animals from surviving long enough
to determine if that process could occur.

The effect of loss of Pot1a on a colitis-induced model of colorectal cancer
The APCmin model mainly produces tumors in the small intestine. To examine the
effect of loss of Pot1a in the colon, we used a model of chemically induced colon cancer that
combines the chemical carcinogen azoxymethane (AOM) and dextran sodium sulfate (DSS)
induced colitis(Neufert et al., 2007). While there are different versions of this protocol with
varying doses of AOM and DSS(Suzuki et al., 2006; Tanaka et al., 2003), we chose to follow
the protocol outlined in Figure 24(Neufert et al., 2007). Briefly, 10-15 week old VCre, Pot1a
animals from each cohort were treated with a single injection of AOM (10mg/kg body
weight). Immediately after the injection, the mice were fed a one week course of 3% DSS
water, followed by two weeks of regular water. This was repeated two more times for a total
of three cycles.
Under this protocol, we expected VCre- wild-type animals to develop multiple large
tumors in the colon by 10 weeks (Becker et al., 2005), therefore tumor evaluation was
performed at this timepoint. However, our cohorts showed very little tumor formation,
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Figure 24: Protocol for AOM/DSS experiment. The protocol for the chemically
induced colon carcinogenesis model is outlined in the figure above. At Day 0, mice
are injected with azoxymethane (AOM) at a concentration of 10mg/kg. A regular diet
was supplemented with 3% dextran sodium sulfate (DSS) water instead of tap water
for a period of one week. Mice were fed regular tap water for two weeks following
DSS treatment. This 3-week cycle was repeated for a total of three times. Mice were
euthanized at 10 weeks to evaluate tumor formation.
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Table 4: Tumor formation in mice treated with AOM/DSS at 10-weeks
Genotype

# animals

# tumors

VCre-

26

3

VCre+

14

0

Pot1aint∆

16

0
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including the VCre- control cohort in which only three tumors were found, one
macroscopically on dissection and two additionally upon histological analysis (Table 4). The
lack of tumor formation in the control mice led us to consider this a failed experiment.
Previous studies have demonstrated the strain differences can affect the susceptibility of mice
to this protocol(Suzuki et al., 2006). Our mice have a mixed background of C57Bl/6 and
129Sv. C57Bl/6 strain is not very susceptible to AOM treatment alone, moderately
susceptible to the combined treatment(Suzuki et al., 2006). We considered the possibility that
the genetic background of our mice was a barrier to tumor formation using this model.
Another possible explanation is that because of the inherent strain resistance to the
treatment, tumor formation occurs after a longer latency in our mice than other strains. To
test this theory, the protocol was repeated with another cohort of mice. In this experiment,
tumor evaluation was performed at 15 weeks instead of 10 weeks. Tumors were seen in mice
from this experimental cohort, but they were still few in numbers and most were very small
(<2mm) (Figure 25A). Quantification of tumor number showed no significant difference in
tumor formation in the VCre- control mice as compared to Pot1aint∆ mice (4.75±3.4 vs. 5.13±
2.7, respectively; t-test; p=0.81)(Figure 25B). Therefore, Pot1a deletion does not appear to
suppress tumor formation in this model. However, future experiments may include delaying
tumor evaluation for a longer period (greater than 20weeks) to determine if telomere
dysfunction has an effect on tumor growth and progression in this model. The low
multiplicity makes the tumor burden easier for the mice to bear, and longer timepoints that
cannot be achieved in the APCmin model may be studied in the AOM/DSS model.
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Figure 25: Tumor formation in mice treated with AOM/DSS at 15 weeks. The
AOM/DSS protocol for chemically inducing colon carcinogenesis was repeated. Eight
animals of each genotype were treated with the same protocol, but tumor evaluation
was conducted at 15 weeks, instead of the previous endpoint of 10 weeks. At this later
time point, more tumors were visualized in the colons of the treated animals (Panel A;
white arrows). Most of these tumors were less than 2mm in size. A comparison of the
tumors found in the two cohorts (Panel B) showed that there was no significant
difference in the number of tumors formed in the control vs. the Pot1aint∆ mice
(p=0.81).
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COMBINED LOSS OF POT1A AND P53 LEADS TO TUMOR FORMATION
p53-dependent activation of p21 and apoptosis serves as a potent checkpoint to stop
propagation of cells with dysfunctional telomeres. Therefore, p53 activity is a key barrier that
keeps dysfunctional telomeres acting in a tumor suppressive fashion and prevents the
transition to telomere dysfunction driving genomic instability and tumor formation. The
importance of this checkpoint was demonstrated in the telomerase null mouse model(Chin et
al., 1999), where p53 deficiency rescued or delayed many of the degenerative phenotypes
seen in late generation mTerc-/- mice, such as testicular atrophy and bone marrow failure.
Telomerase null animals that are deficient in p53 develop tumors(Artandi et al., 2000),
further confirming the importance of this checkpoint for tumor suppression. In fact,
dysfunctional telomeres in this case cooperate with p53 loss to form tumors, and
interestingly, the combination shifts the tumor spectrum from lymphomas and sarcomas to
carcinomas of the breast and gastrointestinal tract(Artandi et al., 2000). p53 deficiency also
allows Pot1a null cells to bypass senescence(Wu et al., 2006). Furthermore, injection of
immortalized Pot1a and p53 double deficient cells into SCID mice produces tumors(Wu et
al., 2006). Based on these data, we hypothesized that abrogation of p53 in our Villin-Cre,
Pot1a mice would allow tumor formation in the gastrointestinal tract.
To generate mice with intestinally deleted Pot1a and p53, we crossed the Villin-Cre,
Pot1a mice with a mouse that contains conditional p53 alleles that are also flanked by loxP
sites(Jonkers et al., 2001). The following cohorts were created for analysis: Pot1aint∆ p53+/+;
Pot1aint∆ p53F/+; Pot1aint∆ p53F/F; and finally p53F/F, which represents mice with only p53
deleted in the intestines. To determine p53 deletion, we employed a PCR strategy developed
by the Berns lab for this allele(Jonkers et al., 2001). Analysis of DNA from several tissues
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demonstrated that deletion of Pot1a and p53 were both still restricted to the small intestines
and colon (Figure 26).

Apoptosis and p21 activation in Pot1a intestines is p53-dependent
Two of the main microscopic features seen in Pot1aint∆ mice are upregulation of p21
and increased apoptotic cells in the crypts. Concurrent upregulation of p53 and the
importance of the p53 checkpoint in the response to dysfunctional telomeres suggest that
these phenotypes are p53-dependent. Comparison of the presence of apoptotic bodies (Figure
27A) in the intestines of the various cohorts revealed that loss of one allele of p53 lead to a
slight but significant decrease in apoptosis (Pot1aint∆ p53+/+: 0.559±0.042 vs. Pot1aint∆ p53F/+:
0.399 ± 0.033, t-test, p = 0.006). Loss of both p53 alleles led to almost complete rescue of the
phenotype with a 4.5-fold decrease in apoptosis (0.123 ± 0.04; t-test, p = 0.0002). Similarly,
upregulation of p21 was also completely abrogated in the setting of p53 deficiency (Figure
27B). These results confirm that the activation of p21 and apoptosis in response to Pot1a loss
are p53-dependent processes.

p53 deficiency allows for more cells with telomere dysfunction to persist
With cell cycle arrest and apoptosis abrogated in p53 deficient animals, we sought to
determine how this affects the cells with telomere dysfunction. Double IF staining to assay
for TIFs in the intestines revealed that p53 deficiency leads to an increase of TIF positive
nuclei in the crypts (Pot1int∆p53+/+: 0.27±0.05 vs. Pot1int∆p53F/F: 0.57±0.13; t-test; p=0.02)
(Figure 28). These results suggest that in the absence of a clearing mechanism, such as
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Figure 26: Verification of Pot1a and p53 deletion in Pot1aint∆∆ p53F/F mice. Using
primers can detect deletion of the Pot1a and p53 alleles, PCR analysis of genomic
DNA isolated from various organs of Pot1aint∆ p53F/F mice show that both genes are
indeed being deleted only in the intestines.
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Figure 27: Apoptosis and p21 activation in Pot1aint∆∆ intestines is p53-dependent.
Comparison on apoptotic bodies on H&E sections of mice from the VCre, Pot1a, p53
mouse colony show that while p53 haploinsufficiency partially decreases the
apoptosis in Pot1aint∆ mice, complete p53 deficiency rescues the phenotype to control
levels (Panel A). Similarly, p21 IHC reveals that p53 deficiency abrogates activation
of this pathway in Pot1aint∆ mice (Panel B). Intestines from four animals per genotype
were examined, and 500 crypts per animal were analyzed.
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Figure 28: p53 deficiency leads to increased numbers of cells with telomere
dysfunction. A tissue TIF assay was performed through double IF, using γ-H2AX
(green) as a marker for DNA damage, and mTRF2 as a marker for telomeres (red).
Nuclei with three or more foci of colocalization were counted as TIF positive. The top
panel contains representative images of TIF positive nuclei from Pot1aint∆ p53F/F mice.
Quantification of intestines from the different cohorts show that loss of p53 leads to an
increase in cells with dysfunctional telomeres in the intestinal crypts. Three mice for
each genotype were examined, and 1000 nuclei from each sample were analyzed.
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apoptosis, cells with telomere dysfunction are allowed to persist and accumulate in the crypts
of the mutant mice.

Mice with combined Pot1a and p53 loss develop invasive adenocarcinomas
Villin-Cre, Pot1a, p53 mice that were allowed to age developed intestinal tumors.
Pot1aint∆ p53F/F mice form tumors in the gastrointestinal tract with almost 100% penetrance
(Table 5). Tumor formation had a long latency, mostly appearing after 15 months of age.
Tumors formed in low multiplicity, with most mice bearing only 1-4 tumors. Pot1aint∆ p53F/+
mice also developed tumors but longer latency and lower penetrance. This is presumably due
to spontaneous LOH of p53. Meanwhile, p53F/F only animals did not form any tumors in the
gastrointestinal tract, suggesting that this process is driven by the combination of p53
deficiency and telomere dysfunction; and loss of p53 is not enough to drive tumorigenesis in
the intestines.
Tumors had two different appearances: cecal masses were rounded polypoid masses
that protrude into the lumen of the cecum (Figure 29A), while tumors found in the small
intestine and colon tended to be flat annular rings, with beaded up borders and depressed
centers (Figure 29B). The flat tumors were difficult to distinguish between irregular
epithelium overlying lymphocytic aggregates (Peyer’s patches) in the intestinal walls, which
looked similar. All tissue taken for further analysis was first confirmed histologically.
Examination of the tumors revealed lesions that ranged from microscopic benign adenomas
to well-differentiated adenocarcinomas that invaded into the submucosa, with some as far as
the muscular wall (Figure 29C). While there was deep invasion into the muscle wall, no
metastasis was observed in any of the animals.
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Table 5: Combined Pot1a and p53 deficiency leads to tumor formation
Genotype

Pot1aint∆ p53+/+

Pot1aint∆ p53F/+

Pot1aint∆ p53F/F

p53F/F

Age range

Animals
tumors

with

Multiplicity

Size range
(longest dimension)

12-24 months

0/15

na

Na

12-15 months

1/7

4

micro

15-18 months

1/6

2

2mm

18-24 months

3/8

1

3mm

12-15 months

3/8

1-2

2-6mm

15-18 months

7/8

1-3

4-15mm

18-24 months

3/3

1-3

3-6mm

12-15 months

0/5

15-18 months

0/6

na

n.a.

18-24 months

0/3
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Cecal tumor
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4x

Figure 29: Combined loss of Pot1a and p53 leads to formation of invasive cancers
in the GI tract. (A) Gross photo of round polypoid cecal tumor. (B) Gross picture of
two small intestine tumors that are flat with raised borders and depressed centers (red
dashed lines). (C) H&E staining of SI and cecal tumors. Regions of invasion (black
dashed box) are shown under higher magnification. Invasion into the submucosa and
muscle wall (dark pink staining, arrows) can be seen.
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Pot1a, p53 intestinal tumors shows signs of genomic instability
DNA was isolated from thirteen tumors grossly dissected from VCre, Pot1a, p53
animals and assayed for genetic alterations through array comparative genomic hybridization
(aCGH) analysis. The genotypes, tumor location and description are listed in Table 6. Tumor
genomes were assayed against DNA pooled from the kidneys of five wild-type females using
the Nimblegen Mouse 385K Whole Genome Tiling Arrays. Whole genome profiles were
generated for each individual tumor (Figures 30 & 31). A few recurrent peaks and large areas
of change are noted with asterisks. Tumors 3 and 6 appear to have the most regions of CNV
with variations in large regions of several chromosomes.
A more detailed analysis of genetic alterations was performed using Biodiscovery’s
Nexus 5 software. The tumors used for array CGH were dissected from the GI tract at the
time of necropsy, and though tumor margins were approximated using a dissection
microscope, there is likely to be normal tissue in the samples. Attempts were also made to
separate some of the muscle wall from the tumors, but H&E staining clearly shows that
tumor cells invaded deep in to the muscle wall and the tumor tissue was mixed with many
other cells types including stromal cells, lymphocytes, submucosal cells and even muscle
wall (Figure 29C). The thresholds were set using the copy number losses of in the X
chromosome of samples from males to determine the baseline setting. This occurred at
approximately -0.2 on the log2 ratio scale. The thresholds were further lowered to -0.1 for a
loss and 0.1 for a gain in an attempt to account for the non-tumor tissue DNA was mixed into
the sample that was analyzed.
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Table 6: Description of tumors used for aCGH experiments
Sample

Genotype

Age
(weeks)

Location

Tumor grade

1

Pot1aint∆ p53F/+

87

Small
intestine

Low-grade adenoma

2

Pot1aint∆ p53F/+

87

Small
intestine

High-grade adenoma

3

Pot1aint∆ p53F/F

78

Small
intestine

Invasive adenocarcinoma

4

Pot1aint∆ p53F/F

63

Small
intestine

Invasive adenocarcinoma

5

Pot1aint∆ p53F/F

63

Colon

High-grade adenoma

6

Pot1aint∆ p53F/F

76

Small
intestine

Invasive adenocarcinoma

7

Pot1aint∆ p53F/F

76

Small
intestine

Invasive adenocarcinoma

8

Pot1aint∆ p53F/F

76

Cecum

Invasive adenocarcinoma

9

Pot1aint∆ p53F/F

76

Colon

Invasive adenocarcinoma

10

Pot1aint∆ p53F/F

65

Cecum

Invasive adenocarcinoma

11

Pot1aint∆ p53F/F

67

Cecum

Invasive adenocarcinoma

12

Pot1aint∆ p53F/F

83

Small
intestine

Invasive adenocarcinoma

13

Pot1aint∆ p53F/F

83

Cecum

Invasive adenocarcinoma
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Figure 30. Tumors from Pot1int∆∆ p53F/F mice show genomic alterations. Whole
genome profiles for Tumors #1-7. The x-axis is divided by chromosomes and the
results for each chromosome are color coded. The y-axis represents the copy number
change on a log2 ratio scale, where the baseline (no change) is set to zero. A few
recurrent peaks and large areas of change are noted with asterisks (*).
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Figure 31. Tumors from Pot1int∆∆ p53F/F mice show genomic alterations. Whole
genome profiles for Tumors #8-13. The x-axis is divided by chromosomes and the
results for each chromosome are color coded. The y-axis represents the copy number
change on a log2 ratio scale, where the baseline (no change) is set to zero. A few
recurrent peaks and large areas of change are noted with asterisks (*).
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Tumor 7
Tumor 8
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Figure 32: Summary of aCGH results for thirteen intestinal tumors. The top
panel represents a summary of genetic alterations seen within the tumor set. The xaxis is divided by chromosomes, from chromosome 1 on the far left, ascending to
chromosome 19 on the right, ending with the X and Y chromosomes on the far right.
The y-axis represents the percent recurrence of each alteration in the tumor set. Green
bars represent copy number gains, while red bars represent copy losses. The bottom
half of the figure displays the changes seen in each individual tumor. Each horizontal
line represents an individual tumor and the variations in each sample can be seen.
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Using these settings, the set of thirteen tumors were analyzed and a summary of the
distribution of changes along the whole genome was generated (Figure 32). Of notes are
several small regions of highly recurrent (present in >50% of tumors) gains and losses on
chromosomes 4, 5, 8, 9, 13, 14 and 19(Figure 32, asterisks).
The total number of regions with copy number variations was determined for each
individual sample (Figure 33). The number of changes per sample ranged from 16 to 97
regions, with a mean of 47.8 changes per tumor. Interestingly, the number of changes does
not seem to correlate with tumor grade as an invasive cecal adenomcarcinoma (tumor #8) had
as few as 27 changes, while a high grade adenoma with no invasion (tumor #2) had as many
as 70 changes. There also seemed to be no correlation between age and copy number change:
an invasive tumor from an 83-week old animal (#12) harbored only 34 regions of CNV,
while a tumor from a 65-week old animal (#10) had 63 changes. This distribution suggests
that each tumor harbors variable numbers of genetic alterations and serves as evidence that
tumors generated by combined Pot1a and p53 deficiency are genomically unstable. The
variation also suggested that the process is stochastic and telomere dysfunction with p53
deficiency is permissive for the formation of random genome changes.

DISCUSSION
The results above describe the generation of a novel mouse model of intestinal tumorigenesis
that is driven by telomere dysfunction. Our model of combined Pot1a and p53 deficiency
proved to be permissive to cancer formation as aging Pot1aint∆ p53F/F mice developed tumors
throughout gastrointestinal tract, including the small intestine, cecum and colon. These
tumors were well-differentiated but showed frequent invasion into the submucosa, with some
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Figure 33: Distribution of copy number changes. The total number of regions with
copy number variations was determined for each sample and plotted above. The
numeric value is listed above the bars. The number of changes per sample ranged from
16 to 97 regions, with a mean of 47.8 changes per tumor.
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extending as deep as the muscle wall. These tumors resemble the GI tumors found in a small
subset of late generation telomerase null mice with p53 haploinsufficiency(Artandi et al.,
2000). Similar to that model, our mice developed tumors with low multiplicity and a latency
of 15 months. However, G5-G7 mTerc-/- p53+/- mice often succumb to other tumor types,
such as lymphomas, breast and squamous cell, and a variety of sarcomas(Artandi et al.,
2000). Additionally, it requires five to seven round of intergenerational breeding to
developed severely shortened telomeres. Our model is superior for studying telomere
dysfunction in the GI tract because our phenotypes are limited to the intestines and we do not
require intergenerational breeding to induce telomere dysfunction.
Genomic profiling of the tumors revealed frequent copy number variation and
heterogeneous profiles, also similar to tumors harvested from telomerase null p53
heterozygous mice(O'Hagan et al., 2002), suggesting that telomere dysfunction was indeed
driving genomic instability. These genomic alterations are currently being worked up to
determine if there are any changes common to what is seen in human cancers and to
determine if there are any new recurrent changes to explore.
It is interesting to note that another group also tried to create a mouse model of
telomere dysfunction in the setting of p53 deficiency in the intestine. This model paired
conditional deletion of p53 in the intestines with late generation telomerase null mice(BegusNahrmann et al., 2009). While they also concluded that p53 deficiency impairs the clearance
of chromosomally unstable cells from intestines with severe telomere erosion, their model
did not develop tumors. They postulated that although their model allowed them to bypass
p53-dependent checkpoints, a second p53-independent checkpoint called crisis prevented
tumor formation in their mice as progressive accumulation of cells with dysfunctional
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telomeres lead to increased apoptosis(Begus-Nahrmann et al., 2009). The crisis checkpoint is
thought to be bypassed in human cancers with the reactivation of telomerase(Maser and
DePinho, 2002), a step that cannot occur in the telomerase null mice. Our model leaves
telomerase activity intact, and may allow for bypass of crisis and possible progression to
metastasis.
Some of the limitations of this model may provide directions that can be pursued in
the future work towards improvement. The long latency of the tumor formation can possibly
be decreased combining the conditional p53 knockout allele with a conventional p53
knockout allele to form p53F/- mice. This would increase the probability of cells with
homozygous deletion of p53 in the intestines because only one additional allele would need
to be deleted conditionally, which may be helpful given the decreased X-gal staining and
presumably decreased Villin-Cre activity in Pot1aint∆ mice. However, this system will only be
beneficial if tumor latency is significantly shortened, as p53 haploinsufficiency throughout
the organism also leads to lymphoma or sarcoma development.
Shortened tumor latency may also prevent the animals from succumbing to
environmental contaminants. Many of our mice were euthanize without any symptoms of
tumor formation. Unfortunately, there was an outbreak of fur mites in our mouse colony
forcing us to euthanize the mice to relieve severe ulcerative dermatitis that was unresponsive
to treatment. Given the invasive nature of the tumors seen on histology and the chromosomal
instability seen on genomic profiling, we postulate that if the mice are allowed to live longer,
we may be able to see more progression.
Another major limitation was the inability to monitor tumor formation. Our mutant
mice developed tumors at a very low multiplicity, only one to four tumors per animal. While

- 75 -

this is an improvement over the APCmin models, which develops dozens of tumors but leads
to early death due to the overwhelming load, low multiplicity means mice could bear the
small tumor burden with few symptoms. In fact, tumor formation was quite insidious and
most of the mice euthanized in this experiment were for symptoms not related to colon
cancer formation. Some techniques that might be used for detection of tumor formation
include in vivo imaging of mice. We attempted several protocols for computed tomography
(CT) scanning and magnetic resonance imaging (MRI), however, the results were not robust
enough to warrant the cost (data not shown). Because the tumors that develop in our Pot1aint∆
p53F/F mice were usually flat and thin, they were difficult to detect using these modalities.
Furthermore, tumors often developed in the small intestines and the tortuous nature of this
organ made it difficult to visualize on scans. We finally settled on using fecal occult blood
testing (FOBT) to look for signs of occult GI bleeding due to tumor formation. The results
from this test showed that positive results on this assay usually required tumors of at least
4mm in size (data not shown). However, results could easily be false positive if the animals
had cuts or sores on its skin that it may have groomed. Future developments in animal
imaging, such as endoscopy, may provide a better method of monitoring tumor formation
and possibly progression.
Another major limitation that prevented further analysis of the tumors was the lack of
material to work with. Several factors contributed to this problem. First, the low multiplicity
of tumor formation in this model limits the number tumors that can be harvested. Second,
while some of the tumors stretched as long as 15mm at its longest dimension, most ranged
between 2-4mm. Furthermore, most tumors fell in the category of flat lesions with raised
edges, so that there was very little volume of tissue to work with. Finally, because this
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morphology mimics irregular epithelium overlying lymphoid aggregates, half of the tumor
was taken tissue sectioning to verify that it was indeed a tumor and determine it grade
through H&E staining. Therefore, we used all of the material harvested from the thirteen
tumors for aCGH was extracted for DNA.
One technique that might help to expand the amount a material available from each
tumor for future experiments is cell culture. Creating cell cultures from tumor tissue would
solve several problems. First, there would be plenty of cells to harvest DNA, RNA and
protein from to perform further validation experiment, especially cytogenetics. Cytogenetic
techniques such as sprectral karyotyping (SKY), have been used previously in verifying
genomic instability and picking up chromosomal translocation induced by telomere
dysfunction(Artandi et al., 2000; Maser et al., 2007). Furthermore, general karyotyping of
genomes could pick up details such as aneuploidy and whole chromosome gains and losses
on a single cell level. Second, cell cultures would help enrich for the colon cancer cells, as
the normal stromal cells surrounding should not grow. We attempted to make cell lines
through several different protocols from intestinal tumors, using the APCmin mice for pilot
studies because of the abundance of lesions in these mice. Unfortunately, we were unable to
produce a culture of growing cells, and there were many incidents of contamination.
Although a lot of antibiotics were used, it was difficult to completely wash away the large
quantities of bacteria that normally inhabit the gut to obtain a sterile culture.
An alternative to cell culture to enrich for tumor cells is laser capture microdissection
(LCM) of tumors from frozen sample. This method would also allow for the isolation of
tumor cells, while limiting contamination from surrounding stromal cells. While this
technique is used at MD Anderson, the aCGH platform we used for our experiments could
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not support materials harvested in this fashion. Perhaps future experiments with different
platforms will be able to take advantage of this technique.
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THE EFFECT OF ATM ON POT1A-INDUCED TELOMERE DYSFUNCTION IN
THE GI TRACT
Animals with combined loss of Pot1a and ATR in the intestinal tract are not viable
Pot1a contributes to the protection of telomeres by suppressing ATR-mediated DNA damage
responses to the G-rich overhang(Denchi and de Lange, 2007; Guo et al., 2007). We sought
to determine the affect of the ATR deficiency in our Pot1aint∆ mouse model by crossing it to a
mouse harboring a conditional knockout allele of ATR (Brown and Baltimore, 2003).
However, we were unable to generate mice with deletion of both genes (Table 7).
This is not a surprising result as loss of ATR is very toxic to cells in culture as it leads to
massive chromosomal fragmentation(Brown and Baltimore, 2003). Also, ATR deficient mice
are not viable due to very early embryonic lethality(Brown and Baltimore, 2000). Previous
experiments using a tamoxifen-inducible Cre system to conditionally knockout ATR in a
grown mouse showed that deletion of ATR leads to transient but severe degenerative
phenotypes in the intestines(Ruzankina et al., 2007). Therefore, it is not surprising that we
were unable to generate many animals with chronic loss of ATR. Because ATR+/- mice
occasionally developed tumors(Brown and Baltimore, 2000), we followed a small cohort of
VCre+, Pot1aF/F, ATRF/+ mice for two years, but no tumor formation or intestinal
abnormalities were detected (data not shown).
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Table 7: Results of VCre+ Pot1aF/F ATRF/+ x VCre- Pot1aF/F ATRF/+
Genotypes

Expected

# Observed

% observed

VCre- Pot1a F/F ATR+/+

1/8 (12.5%)

14

17.3%

VCre- Pot1a F/F ATR F/+

1/4 (25%)

22

27.2%

VCre- Pot1a F/F ATR F/F

1/8 (12.5%)

12

14.8%

VCre+ Pot1a F/F ATR +/+

1/8 (12.5%)

15

18.5%

VCre+ Pot1a F/F ATR F/+

1/4 (25%)

25

30.9%

VCre+ Pot1a F/F ATR F/F

1/8 (12.5%)

*1

1.2%

Total:

89 mice

* Mouse survived for 4 weeks.
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ATM loss results in decreased overall survival
While Pot1a mainly suppresses ATR-mediated DNA damage responses, deletion of
Pot1a has been shown to also activate ATM(Wu et al., 2006). Furthermore, stable disruption
of TPP1, whose main function is to facilitate Pot1a binding to telomeres, also leads to
activation of the ATM pathway(Guo et al., 2007). It is postulated that while the immediate
response to Pot1a loss is ATR-activation, ATM may also plays a role in a later response.
Since in vivo deletion of Pot1a represents a chronic process, we sought to determine if loss of
this checkpoint affected the phenotypes of our Pot1a mutants. To achieve this, we crossed
our VCre, Pot1a mice with an ATM knockout mouse(Borghesani et al., 2000). This mouse
was a straight knockout, so that ATM loss occurs throughout the entire organism. As seen in
ATM-/- mice, these animals showed in shortened lifespan due to formation of thymic
lymphoma (Figure 34), regardless of Pot1a status in the intestines.

ATM deficiency rescues p21 activation and apoptosis
A few mice were sacrificed at early timepoints (10 weeks) to examine the intestines for the
microscopic characteristics seen in Pot1aint∆ crypts. Interestingly, in the setting of ATM
deficiency, Pot1a loss does not manifest in increased apoptosis in the intestinal crypts
(Pot1aint∆ ATM+/+: 0.60±0.12 vs. Pot1aint∆ ATM-/-: 0.17±0.08; t-test; p=0.05) (Figure 35A).
Furthermore, examination of p21 IHC staining revealed that activation of p21 is also
abrogated in Pot1a and ATM deficient intestines (Pot1aint∆ ATM+/+: 3.71±0.54 vs. Pot1aint∆
ATM-/-: 0.23±0.07; t-test; p<0.001) (Figure 35B&C). These results suggest that p53
activation is not occurring in the absence of ATM. We postulate that loss of ATM may be
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Figure 34: ATM deficiency leads to early death in Pot1a deficient mice. KaplanMeier analysis showed that ATM deficiency lead to decreased overall survival,
regardless of Pot1a status.
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Figure 35: ATM deficiency rescues apoptosis and p21 activation in Pot1int∆∆
crypts. (A) H&E staining of intestines harvested from various cohorts were examined
for apoptosis. Quantification of apoptotic bodies per crypt demonstrated that ATM
deficiency leads to decreased apoptosis in Pot1int∆ intestines as compared to
Pot1int∆ ΑΤΜ+/+  (B) Representative p21 IHC staining in Pot1aint∆ ΑΤΜ+/+ and
Pot1int∆ ΑΤΜ−/− intestines. p21 positive nuclei are indicated by the arrows. (C)
Quantification of IHC staining shows a decrease in p21 activation in Pot1a deleted
intestines when ATM is also deficient.
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interfering with the DNA damage response to dysfunctional telomeres but recent attempts to
assay for TIFs have been unsuccessful.

Pot1aint∆∆ ATM+/- mice occasionally develop intestinal tumor formation in the aged mice
While ATM-/- mice did not survive very long, we followed a cohort of
Pot1aint∆ ΑΤΜ+/− mice for a period of two years. Routine euthanasia of these mice revealed
occasional tumor formation in aged mice (Table 8). Of the sixteen mice older than 18 months
that we examined, only four mice were observed to have tumors. These tumors were mostly
well-differentiated adenomas, with one tumor showing signs of invasion. We postulated that
loss of the wild-type ATM allele was necessary for tumor formation, but PCR experiments to
verify this have been inconclusive. Taken together, these results suggest that loss of the ATM
barrier may also be permissive to driving tumor formation in the setting of telomere
dysfunction, possibly through the prevention of p53 activation in response to telomere
dysfunction secondary to Pot1a loss.

Discussion
Pot1a binds specifically to the 3’ G-rich overhang of telomeres. It is has been shown
contribute to the protection of telomeres from the DNA damage response by preventing the
activation of an ATR-dependent DDR(Denchi and de Lange, 2007; Guo et al., 2007). We
sought to determine the effect of losing this checkpoint in our in vivo model of Pot1a
deficiency by generating a VCre+ Pot1aF/F ATRF/F mouse. However, we were unable to
produce this mouse. This result is not surprising given that ATR is an essential gene for cell
survival(Brown and Baltimore, 2003). Deletion of ATR from cells in culture lead to rapid
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Table 8: Pot1aint∆∆ ATM+/- mice occasionally form tumors
Age range
12-15 months

Animals
tumors
0/4

15-18 months

with multiplicity
n.a

Size range
(diameter)
n.a.

0/5

n.a.

n.a.

18-21 months

1/4

1

3mm

21-24 months

3/12

1-2

3-8mm

Non-invasive Pot1aint∆ ATM+/- adenocarcinoma
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chromosomal instability and cell death(Brown and Baltimore, 2003). Conditional deletion of
the ATR in mice using an inducible Cre system resulted in massive cell death in highly
proliferative compartments, especially in the intestinal tract(Ruzankina et al., 2007).
Since we were unable to remove the ATR checkpoint, we decided to target ATM,
which is also a potent transducer of the DNA damage response. In response to telomere
dysfunction, ATM activation is typically associated with severe telomere erosion or loss of
the TRF2 protein(Karlseder et al., 1999), both of which are thought to resemble double
strand breaks. However, there is some evidence that ATM activation may play a role in the
response to Pot1a loss. Western blots performed on cells that have lost Pot1a(Wu et al.,
2006) or stably express a TPP1-mutant that prevents Pot1a from binding to telomeres
(TPP1∆RD)(Guo et al., 2007) show activation of ATM. Those results suggest that ATMmediated DDR may play a role in chronic loss of Pot1a.
These results from this model suggest that ATM is necessary for activation of p53 in
response to Pot1a loss, as Pot1aint∆ ATM-/- intestines fail to activate apoptosis and p21. These
results are surprising because ATM deficiency does not affect the DDR to shortened
telomeres in late generation telomerase null mice(Wong et al., 2003). This may suggest that
ATM response to telomere uncapping due to Pot1a deletion triggers a different ATM
response than critically short telomeres.
A small subset of aging Pot1aint∆ ATM+/- produce tumors in the gastrointestinal tract,
suggesting that abrogation of the ATM DNA damage checkpoint may also be a good model
for telomere driven intestinal tumorigenesis. If this model is to be pursued further, I would
recommend using a conditional ATM knockout allele to restrict ATM deletion to the

- 86 -

intestinal. This would bypass the early death caused by thymic lymphoma to allow the
Pot1aint∆ ATM-/- GI phenotype time to manifest, possibly shortening tumor latency.
Finally, future work may combine Pot1a deletion with both p53 and ATM deficiency.
Loss of both barriers to genomic stability may provide a model with shorter tumor latency
and more chromosomal changes. Previous experiments have combined p53 and ATM
deficiency with the telomerase knockout mouse to generate a model of lymphoma with
unstable genomes (Maser et al., 2007). Work from this model has suggested that genetic
changes seen in tumors with unstable genomes driven by telomere dysfunction, p53 and
ATM deficiency, are similar to those seen in a variety of human tumors(Maser et al., 2007).
These results suggest that genetic information found in tumors from these mouse models can
be used as a filter for deciphering important genetic changes in human tumors. Perhaps future
work with our Pot1a conditional model can yield such information to facilitate new gene
discoveries based on telomere dysfunction in gastrointestinal tumors or other organ systems.
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CONCLUSIONS AND FUTURE DIRECTIONS

The results of this manuscript describe the generation of a novel mouse model of
intestinal tumorigenesis that is driven by telomere dysfunction. Taking advantage of the
similar effects of telomere uncapping due to loss of the Pot1a telomere binding protein, we
first created a mouse model of telomere dysfunction in the gastrointestinal tract that does not
require multiple rounds of intergenerational matings necessary in the telomerase knockout
models. First, we created a novel mouse model of telomere dysfunction in the gastrointestinal
tract through the targeted deletion of the telomere binding protein, Pot1a. While our model
does not show the overall morphological features of critical telomere shortening, such as
blunting or atrophy of villi(Rudolph et al., 1999), the VCre, Pot1a mice developed various
microscopic changes in the intestinal epithelium that are similar to late generation telomerase
null animals with critically short telomeres (Choudhury et al., 2007; Rudolph et al., 1999).
Pot1a deletion led to increased apoptotic cells in the crypts, as well as upregulation of p53
and p21 expression. Finally, Pot1a deletion leads to increased cells with TIFs, an indicator of
activation of the DDR in response to dysfunctional telomeres. These data correspond to
previous work in cell culture, which has shown that deletion of Pot1a leads to a DNA
damage response, which activates p53 to trigger cell cycle arrest through p21 or apoptosis
(Wu et al., 2006), supporting the conclusion that in vivo consequences of Pot1a deficiency is
similar to those seen in vitro.
Our second mouse model featuring combined Pot1a and p53 deficiency proved to be
permissive to cancer formation as aging Pot1aint∆ p53F/F mice developed tumors throughout
gastrointestinal tract, including the small intestine, cecum and colon. These tumors were
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well-differentiated but showed frequent invasion into the submucosa, with some extending as
deep as the muscle wall. These tumors resemble the GI tumors found in a small subset of late
generation telomerase null mice with p53 haploinsufficiency(Artandi et al., 2000). Similar to
that model, our mice developed tumors with low multiplicity and a latency of 15 months.
However, G5-G7 mTerc-/- p53+/- mice often succumb to other tumor types, such as
lymphomas, breast and squamous cell, and a variety of sarcomas(Artandi et al., 2000).
Additionally, it requires five to seven round of intergenerational breeding to developed
severely shortened telomeres. Our model is superior for studying telomere dysfunction in the
GI tract because our phenotypes are limited to the intestines and we do not require
intergenerational breeding to induce telomere dysfunction.
It is interesting to note that another group also tried to create a mouse model of
telomere dysfunction in the setting of p53 deficiency in the intestine. This model paired
conditional deletion of p53 in the intestines with late generation telomerase null mice(BegusNahrmann et al., 2009). While they also concluded that p53 deficiency impairs the clearance
of chromosomally unstable cells from intestines with severe telomere erosion, their model
did not develop tumors. They postulated that although their model allowed them to bypass
p53-dependent checkpoints, a second p53-independent checkpoint called crisis prevented
tumor formation in their mice as progressive accumulation of cells with dysfunctional
telomeres lead to increased apoptosis (Begus-Nahrmann et al., 2009). The crisis checkpoint
is thought to be bypassed in human cancers with the reactivation of telomerase(Maser and
DePinho, 2002), a step that cannot occur in the telomerase null mice. Our model leaves
telomerase activity intact, and may allow for bypass of crisis and possible progression to
metastasis.
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Our final mouse model paired loss of Pot1a with ATM deficiency. In response to
telomere dysfunction, ATM activation is typically associated with severe telomere erosion or
loss of the TRF2 protein(Karlseder et al., 1999), both of which are thought to resemble
double strand breaks. However, there is some evidence that ATM activation may play a role
in the response to Pot1a loss. Cell culture experiments with cells deficient in Pot1a(Wu et al.,
2006) or cells with mutant TPP1(Guo et al., 2007) can lead to ATM activation, suggesting
that ATM-mediated DDR may play a role in chronic loss of Pot1a. The phenotypes seen in
our VCre, Pot1a, ATM mouse models support this theory and further suggest that ATM is
necessary for activation of p53 in response to telomere uncapping, as Pot1aint∆ ATM-/intestines fail to activate apoptosis and p21. These results are surprising because ATM
deficiency does not affect the DDR to shortened telomeres in late generation telomerase null
mice(Wong et al., 2003). This may suggest that ATM response to telomere uncapping due to
Pot1a deletion triggers a different ATM response than critically short telomeres.
Furthermore, a small subset of aging Pot1aint∆ ATM+/- produce tumors in the gastrointestinal
tract, suggesting that abrogation of the ATM DNA damage checkpoint may also be a good
model for telomere driven intestinal tumorigenesis.
The phenotypes seen in the p53 and ATM colonies suggest that a combination of
Pot1a loss with both p53 and ATM deficiency may possibly result in a model with even more
pronounced phenotypes. Loss of both barriers to genomic stability may provide a model with
shorter tumor latency and more chromosomal changes. Previous experiments have combined
p53 and ATM deficiency with the telomerase knockout mouse to generate a model of
lymphoma with unstable genomes (Maser et al., 2007). Work from this model has suggested
that genetic changes seen in tumors with unstable genomes driven by telomere dysfunction,
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p53 and ATM deficiency, are similar to those seen in a variety of human tumors(Maser et al.,
2007). These results suggest that genetic information found in tumors from these mouse
models can be used as a filter for deciphering important genetic changes in human tumors.
Perhaps future work with our Pot1a conditional model can yield such information to facilitate
new gene discoveries based on telomere dysfunction in gastrointestinal tumors or other organ
systems.
Genomic profiling of the VCre, Pot1a, p53 tumors revealed frequent copy number
variation and heterogeneous profiles, which is similar to tumors harvested from telomerase
null p53 heterozygous mice(O'Hagan et al., 2002), suggesting that telomere dysfunction was
indeed driving genomic instability. Genetic diversity and the wide variation of tumor
genomes is one of the barriers to development of effective treatments for solid tumors, such
as colorectal cancer. It is the reason why one patient treated with a particular drug can go into
remission, while that same therapy will have no effect on another patient’s tumor. Future
work with this model may also elucidate new gene mutations and genetic pathways to target
with therapeutics.
One major limitation of this model was the inability to monitor tumor formation.
However, there are new techniques for in vivo imaging of mouse models that are currently
being developed and used at other institutions. For instance, it is now possible to perform
endoscopic imaging of mouse intestines using fiber optic technologies (Becker et al., 2005).
If these techniques can be applied to our model, one could imagine even more questions that
these mice can be use to answer. For instance, if endoscopic techniques for the mouse GI
tract can be modified to take biopsies early and late during tumor develop, we could compare
the genetic make-up or protein expression to look for targets involved in cancer progression.
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This technique could also open up the possibility of using this mouse model for testing
therapeutics. It would allow for monitoring of tumors for treatment effect as growth or
regression could be monitored while sparing the animal from early euthanasia. Also,
profiling pre-treatment biopsies may allow us to determine which genomic changes make a
tumor more susceptible or more resistant to a particular type of treatment. For these
applications, the variable genetic profiles of tumors from one animal to another more closely
recapitulate the diversity of human tumors, making it a unique model for studying these
phenomena.
Advances in cancer genomics are fueling the push towards personalized medicine, the
idea that treatment regimens can be individualized to each person’s tumor according to its
genetic make-up. The unique nature of this mouse model of sporadic colon cancer driven by
telomere dysfunction may provide a valuable tool for preclinical trials of therapeutics based
on this concept.
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MATERIALS AND METHODS

DNA extraction from tissue
Tissue was harvested from animals at autopsy and rinsed immediately with ice cold
phosphate buffered saline (PBS). Intestinal samples were obtained by scraping epithelial
cells with a scalpel. Tissue was digested using 450µl Cell Lysis Solution (Qiagen) and
10µl Proteinase K (20mg/ml) at 55oC overnight. Samples were then treated with RNase A for
30 min – 1 hour at 37oC. After addition of Protein Precipitation Solution (Qiagen), samples
were spun for 30 minutes at 13,000 rpm. The DNA was precipitated from the supernatant
with isopropanol and spun down. After washing with 70% ethanol, DNA pellets were air
dried and the resuspended in 1X TE. Purity of samples was determined through Nanodrop
and 1% agarose gels. If further purification was necessary, the samples were mixed with an
equal volume of phenol-chloroform and spun down. The top aqueous layer was transferred to
a new tube and the process was repeated. Then the top layer was transferred to a new tube,
mixed with an equal volume of chloroform and spun down. DNA was precipitated with the
top aqueous layer with 1/10 volume of 3M NaOAc, 3 times volume of 100% ethanol and
incubated at -20oC for 2 hours. After spinning down, the pellet was air dried and then
resuspended in 1xTE.

Genotyping of animals and tissue
Genotyping of animals was accomplished through PCR of tail or tissue DNA using primers
and protocols previously described for each mouse line (Table 9).
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Paraffin-embedding and H&E staining of tissue
Tissues harvest from animals at autopsy was rinsed with ice cold PBS immediately. Nonintestinal tissues were placed into cassettes and fixed in 10% formalin (Fisher) at room
temperature for 24-48hrs. Cassettes were then transferred to 70% ethanol for storage before
further processing. Intestines were dissected from the animal and washed in ice-cold PBS.
They were further cleaning by flushing the lumen with ice cold PBS using a 10ml syringe
and an 18g-feeding needle. The tissue was then fixed in 10% formalin for 24-48hrs at room
temperature. The intestines were then cut open longitudinally and rolled with forceps. The
Swiss rolls were pinned with a 26-gauge needle and stored in 1xPBS for 24-48hrs. The
intestinal rolls were then sliced in half, placed in cassettes, and stored in 70% ethanol until
further processing. The samples were then submitted to the MD Anderson Histology CORE,
where the tissue were embedded in paraffin and cut into 5 micron section. Hematoxylin and
eosin (H&E) staining was also performed at the Histology CORE according to standard
protocols.

TUNEL assay
TUNEL assay was performed on paraffin embedded tissue using the Apoptag Kit (Millipore)
according to the instructions. Briefly, paraffin-embedded tissue sections were run through a
xylene to alcohol gradient and rinsed with 1x PBS. The sections were pretreated with a
Proteinase K solution (20µg/ml) for 15 minutes at room temperature. After washing with
ddH2O, the slides were then quenched with 3% H2O2 for 5 minutes at room temperature.
Slides were rinsed with 1xPBS and then incubated briefly with Equilibration buffer. The
slides were treated with TdT enzyme for one hour at 37oC. The reaction was stopped
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STOP/wash buffer for 10 minutes at room temperature. Anti-digoxigenin solution was
applied for 30 minutes at room temperature, followed by washes with 1x PBS. The DAB
solution (Vector) was prepared with 2 drops, buffer, 4 drops reagent, 2 drops H2O2, and 2
drops nickel in 5ml H2O, and applied to the specimen for 3-6 minutes. The slides were
washed with water before counterstaining with Nuclear Fast Red (H-3403, Vector) for 45
seconds to 1 minute, followed by more washing. The sections were through a reverse alcohol
to xylene gradient and a glass coverslip was mounted with Permount. Analysis of TUNEL
slides were performed on the Nikon 80i Upright Microscope using the NIS-Elements AR 3.1
software.

Immunohistochemical (IHC) staining
IHC staining on paraffin embedded tissue sections was performed at the Histology and
Tissue Processing Facility Core at MDACC Science Park – Research Division in Smithville,
Texas. Tissue sections were stained for p53 and p21 according to their standardized
protocols. Slides were analyzed through brightfield microscopy on a Nikon 80i Upright
Microscope and pictures were taken using NIS-Elements AR 3.1 software.

Immunofluorescence (IF) staining
Sections of paraffin embedded tissue were run through a xylene to alcohol gradient and
rinsed with ddH2O. Epitope retrieval was performed with Antigen Unmasking Solution
(Vector) diluted 1:100 in ddH2O, steamed for 45 minutes, and cooled for 25 minutes. Slides
were rinsed with ddH2O and then 1xPBS. Slides were blocked with 10% goat serum/PBS for
30 minutes to 1 hour at room temperature. Sections were incubated with primary antibodies
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diluted in 10% goat serum/PBS at 4oC overnight. For double staining, both primaries were
added at the same time. The primary antibodies were diluted in the following manner: mouse
monoclonal γ-H2AX (Millipore #05-636; 1:200), rabbit polyclonal γ-H2AX (Millipore #07164; 1:200), mTRF2 (1:200), BrdU (BD #347580; 1:100), beta-catenin (BD #610153;
1:100), Cox-2 (Cayman #160162; 1:100). After washing with PBS, Alexa-conjugated
fluorochromes (see below) were diluted 1:200 in 10% goat serum/PBS and incubated at room
temperature for 1 hour. Slides were rinsed with PBS, and then samples for fluorescent
microscope analysis were mounted with Vector Shield mounting media with DAPI. Samples
for confocal analysis were counterstained with TO-PRO-3 (Invitrogen #T3605), diluted
1:1000 at room temperature for 20 minutes. After another rinse with PBS, the coverslip was
mounted on with Slowfade Gold (Invitrogen #S36936).

Fluorescence microscopy was

performed on a Nikon Eclipse 80i microscope using MetaMorph software. Confocal imaging
was performed on a Zeiss LSM 510 Confocal microscope.
Secondary antibodies used included: Alexa Fluor 568 goat anti-rabbit (Molecular
Probes #A11011), Alexa Fluor 568 goat anti-mouse (Molecular Probes #11004), Alexa Fluor
488 goat anti-rabbit (Molecular Probes #A11070) and Alexa Fluor 488 goat anti-mouse
(Molecular Probes #A11001).

β-galactosidase activity assay
Tissues were dissected from animals at the time of autopsy, washed with ice cold PBS, and
fixed in 4% paraformaldehyde on ice for 20 minutes. Tissues were then embedded in OCT
and flash frozen. 10 micron frozen tissue sections were cut in a cryostat and immediately
fixed with 0.2% glutaraldehyde for 2 minutes and then immersed in X-gal staining solution
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(1mg/ml X-gal, 5mM potassium ferricyanide, 5mM potassium ferrocyanide, 0.2% NP-40,
0.1% sodium deoxycholate, 2mM MgCl2) overnight at 37oC. Slides were then washed in
PBS before going through an alcohol to xylene gradient. Coverslip was mounted with
Permount. Slides were analyzed through brightfield microscopy on a Nikon 80i Upright
Microscope and pictures were taken using NIS-Elements AR 3.1 software.

RT-PCR
Tissue was harvested from animals at autopsy and flash frozen. RNA isolation was
accomplished using Trizol as outlined by the product guide. Briefly, tissue was homogenized
in 1ml Trizol and then incubated at room temperature for 5 min. 200µL of chloroform was
added and the sample was incubated for an additional 3 minutes at room temperature.
Centrifuge at 13,000 rpm for 15min at 4oC. The top aqueous layer was transferred to a new
tube. 500µl of isopropanol was added and the sample was then incubated at room
temperature for 5 min. Centrifuge 13,000 rpm for 10min at 4oC. Discard supernatant and
wash with 70% ethanol. Spin down and air dry the pellet. Resuspend in RNase/DNase free
water.
RT-PCR was performed directly with RNA using the Taqman One Step RT-PCR
Mastermix (Applied Biosystems/Roche). Pot1a was assayed using Taqman Custom Gene
Expression Assay probes for exon 4. Results were normalized to GAPDH expression, which
was determined with Taqman murine GADPH primers. All samples were run in triplicate.
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Chemical induction of colon tumors (AOM-DSS model)
10-15 week old VCre, Pot1a animals from each cohort were treated with a single injection of
AOM (10mg/kg body weight). Immediately after the injection, the mice were fed a one week
course of 3% DSS water, followed by two weeks of regular water. This was repeated two
more times for a total of three cycles. Tumor evaluation was performed at 10 weeks or 15
weeks after the AOM injection.

Irradiation experiments
Mice were dosed in the Mark I25 irradiator which has a 137Cs line source. The mice were first
placed in a plastic CD contained with ventilation holes punched in. The time of exposure was
calculated by the following equation:
Time =

desired dose (cGy)

- 0.005min

0.98 x 315 cGy*min-1

Array comparative genomic hybridization (aCGH)
Array CGH was performed by the MD Anderson Genomics CORE on a Nimblegen 385K
Whole genome tiling array (Roche). DNA was extracted from tumors as described above.
Control DNA was pooled from the kidneys of five wild-type female mice. Raw data was
processed with Imagene by the Core. Analysis was performed using the Nexus 5 software
with the following settings: High gain = 0.5, gain = 0.1, loss = 0.1, big loss = -0.5.
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Table 9: Genotyping primers and conditions
Genotype
Pot1a
(WT/ floxed)
Pot1a
(delta)
P53
(WT/ floxed)
P53
(delta)
P53
(KO)
ATM
Villin-Cre

APCmin
Rosa26-LacZ
(R26R)
ATR

Primer sequence
EcoRI-21196: 5’- CTC GAA TTC CAT CTC CTC
CCA GTA CTC TCT CAG
Confirm_20560: 5’- GGA ACT GGT ACG TAT CAG TGT
GTG TGG
EcoRI_21196: 5’- CTC GAA TTC CAT CTC CTC
CCA GTA CTC TCT CAG
Delta: 5’- ACA CGG ATC CTG AGC CAT AAA CAT
GCC ACA CAA AGG
p53loxFWB 5'- AAG GGG TAT GAG GGA CAA GG
p53loxRVB
5'- GAA GAC AGA AAA GGG GAG GG

Conditions
94oC 0:30
60oC 0:30
72oC 1:00 x 30 cycles
94oC 0:30
60oC 0:30
72oC 1:00 x 30 cycles

94oC
60oC
72oC
p53-1F: 5’- CAC AAA AAC AGG TTA AAC CCA G
94oC
p53loxRVB
5'- GAA GAC AGA AAA GGG GAG GG
60oC
72oC
P53X7: 5’- TAT ACT CAG AGC CGG CCT
94oC
P53X6-5: 5’- ACA GCG TGG TGG TAC CTT AT
62oC
neoP53: 5’- TCC TCG TGC TTT ACG GTA TC
72oC
CZ514: 5’- GTA GTA ACT ATT AGT TTC GTG CA
94oC
CZ513: 5’- TAG GGT GTA CTA GTG GAG GA
55oC
CZ054: 5’- GCT GGA CGT AAA CTC CTC TTC AGA C
72oC
MVP+5498: 5’- ACA GGC ACT AAG GGA GCC AATG
94oC
MVP+6378: 5’- GAT TCA GGT CAG AAA GAG GTC ACA 59oC
G
72oC
CreORF:
5’- CAT GTC CAT CAG GTT CTT GCG
IMR0033: 5’- GCC ATC CCT TCA CGT TAG
IMR0034: 5’- TTC CAC TTT GGC ATA AGG C
IMR0758: 5’- TTC TGA GAA AGA CAG AAG TTA

1:00
1:00
1:00
1:00
1:00
1:00
1:00
1:00
1:00
0:40
0:40
0:45
1:00
1:00
1:30

x 35 cycles

x 35 cycles

x 30 cycles

x 30 cycles

x 35 cycles

94oC 0:30
55oC 1:00
72oC 1:30 x 35 cycles
IMR0315: 5' - GCG AAG AGT TTG TCC TCA ACC
94oC 0:30
IMR0316: 5'- GGA GCG GGA GAA ATG GAT ATG
65oC 0:45
IMR0883: 5'- AAA GTC GCT CTG AGT TGT TAT
72oC 1:00 x 35 cycles
GATR-I#5: 5’-TAC ATT TTA GTC ATA GTT GCA TAA Ramp 1.5oC/s to 94oC
CAC
94oC 1:00
GATR-I#15: 5’- CTT CTA ATC TTC CTC CAG AAT TGT Ramp 1.5oC/s to 62oC
AAA AGG
62oC 2:30
Ramp 1.5oC/s to 72oC
72oC 2:30 x 35 cycles
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